#kitenews: We'll be presenting new data at #ash26 with @GileadSciences to illustrate progress across our pipeline and portfolio. Read more: gilead.inc/3WJl4AQ
Kite Pharma
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017. More on Wikipedia
-
Kite, a Gilead Company
@KitePharma
-
Kite, a Gilead Company reposted
STAT Brand Studio
@statbrandstudio
Driven by a deep heritage in science, @GileadSciences and @KitePharma are establishing their leadership in oncology.
Dietmar Berger, Chief Medical Officer of Gilead, shares his perspective on how advances in science, technology and collaboration are shaping their vision for the future of cancer care: www.statnews.com/sponsor/2026/07/20/changing-whats-possib…This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company reposted
STAT Brand Studio
@statbrandstudio
How can innovation in oncology become more meaningful for patients? Dr. Mika Kakefuda Derynck of @GileadSciences and Dr. Gallia Levy of @KitePharma discuss advances in ADCs, CAR T-cell therapies and what it will take to bring these innovations to more people living with cancer.
-
Kite, a Gilead Company reposted
Penn Medicine
@PennMedicine
Differences in immune activation might explain why some patients with glioblastoma respond to dual-target CAR T cell therapy—and some do not. @Penn_CBIO @PennNSG www.pennmedicine.org/news/immune-activation-predicts-dual…
-
Kite, a Gilead Company reposted
STAT Brand Studio
@statbrandstudio
Cancer care is becoming increasingly personalized.
At STAT@ASCO, @GileadSciences CMO Dietmar Berger discussed how advances in cell therapy, antibody-drug conjugates, and other targeted approaches are helping researchers pursue new ways to treat cancer and improve outcomes for patients. -
Kite, a Gilead Company
@KitePharma
Thank you to our research team for representing Kite in Washington, D.C., helping shape policies that support innovation and the development of therapies for patients. #phrmaflyin26
-
Kite, a Gilead Company
@KitePharma
Advancing science requires a policy environment that supports innovation. Today, our research team is engaging with policymakers to advocate for evidence-based legislation that protects the R&D ecosystem and helps bring next-generation treatments to patients. #phrmaflyin26
-
Kite, a Gilead Company
@KitePharma
#kitenews: We'll be at #asco26 and #eha2026 with @GileadSciences to present data highlighting advances in our cell therapy and antibody-drug conjugate programs. Read more on our progress in developing treatment options for people living with cancer: gilead.inc/3PHgW10
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
#gileadnews: Today, we completed our acquisition of Arcellx, which strengthens our oncology portfolio and the long-term potential of an investigational cell therapy for multiple myeloma. Read more: gilead.inc/48rJHVO
-
Kite, a Gilead Company
@KitePharma
#kitenews: The @US_FDA has granted traditional, full approval to our CAR T-cell therapy for adults with relapsed or refractory mantle cell lymphoma. We’re committed to advancing innovative treatments for patients with a variety of blood cancers. Read more: gilead.inc/4vpafkz
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
#gileadnews: We have entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
Read more: www.gilead.com/news/news-details/2026/gilead-sciences-to-… -
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
#gileadnews: We reached an agreement to acquire @arcellx, supporting an investigational cell therapy for multiple myeloma. FDA acceptance of the BLA marks an important milestone. Read more: gilead.inc/4qMWh8x
-
Kite, a Gilead Company
@KitePharma
#kitenews: The @US_FDA approved a label update for our CAR T-cell therapy, which removed the Limitations of Use in relapsed or refractory primary central nervous system lymphoma based on safety data. www.kitepharma.com/news/press-releases/2026/2/fda-approve…
-
Kite, a Gilead Company
@KitePharma
This #worldcancerday, we honor the individuality of every patient, survivor and caregiver whose journey inspires progress. We’re dedicated to keeping patients and their unique voices at the center of our work as we deliver meaningful improvements in cancer care. #unitedbyunique
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Cue the highlights: standout moments, innovative science and meaningful progress across Gilead and @KitePharma in 2025. From major global achievements to everyday team accomplishments, this work helped define who we are, where we’re going and how far we still want to go.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Welcome back to a Tiny CAR T Story. In this episode, we’re breaking down the science of how CAR T-cells play “hide and seek” in the body to find, detect and destroy the cancer cells that try to hide in the body.
-
Kite, a Gilead Company
@KitePharma
From a blood cancer diagnosis to dancing at her son’s wedding, Allie’s journey shows the transformative science of CAR T-cell therapy. Her story reminds us why we remain committed to the potential of achieving cures with cell therapy.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
#kitenews: We're presenting a new pooled analysis highlighting safety & efficacy data and observed quality of life benefits of our treatment in R/R large B-cell lymphoma at #ash25. Learn how this may help further establish a new standard of care: www.kitepharma.com/news/press-releases/2025/12/yescarta-d…
-
Kite, a Gilead Company
@KitePharma
#kitenews: Early Phase 1 clinical findings presented at #ash25 suggest our bicistronic cell therapies may have the potential to transform care for people with R/R B-cell lymphoma. Read more: www.kitepharma.com/news/press-releases/2025/12/kites-next…
-
Kite, a Gilead Company
@KitePharma
#kitenews: New pivotal Phase 2 data presented at #ash25 with @Arcellx may help redefine care and offer hope for people with relapsed or refractory multiple myeloma. Learn more about the results: www.kitepharma.com/news/press-releases/2025/12/kite-annou…
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
On #idpd, we celebrate the contributions of individuals with disabilities and reaffirm our commitment to accessibility and equal opportunity. Our #disabilityinclusion employee resource group continues to advance this work to foster belonging for all. gilead.inc/4rPnRUm
-
Kite, a Gilead Company
@KitePharma
We’re proud to join thousands of clinicians, researchers and advocates at #ash25 to share the latest updates on our cell therapy innovation, redefining what’s possible for people with cancer.
-
Kite, a Gilead Company
@KitePharma
We believe more is possible. That’s why we're dedicated to ensuring every appropriate patient who needs CAR-T cell therapy can access it by expanding our treatment center network to help bring potentially curative treatments closer to patients around the world.
-
Kite, a Gilead Company
@KitePharma
Behind Kite’s innovative science is a team driven by something bigger: a shared commitment to improving patients’ lives. Ani Avanesian exemplifies that spirit. For her, the most rewarding part of the job is knowing the work helps bring hope to patients and their families.
-
Kite, a Gilead Company
@KitePharma
For Mark Hurvitz, discipline, integrity and service are the guiding principles behind everything he does. As a veteran and Associate General Counsel at Kite, Mark brings his lessons from the military to his work supporting Kite’s manufacturing and quality teams. #veteransday
-
Kite, a Gilead Company
@KitePharma
To honor those impacted by blood cancer, we joined #bloodcancerunitedlightthenight in LA to celebrate the advances in research and treatment that continue to drive us forward. We’re inspired by @BloodCancerUtd, and everyone who continues to be a light on the journey to a cure.
-
Kite, a Gilead Company
@KitePharma
#kitenews: At #ash25, we’re sharing data across our portfolio and pipeline of CAR T-cell therapies, including from the pivotal iMMagine-1 Phase 2 study in multiple myeloma. Read how we’re aiming to transform blood cancer care with @GileadSciences: www.kitepharma.com/news/press-releases/2025/11/gilead-and…
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Bhavna’s commitment to the community enables her team to innovate and transform how cancer is treated. Together with @KitePharma, we’re collaborating to address the greatest gaps in care.
-
Kite, a Gilead Company
@KitePharma
Our cell therapy specialists begin their day with a critical step: gowning in. This process ensures they’re ready to enter the lab and create CAR T-cell therapies where capacity, speed and reliability matter for the patients we serve.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
As many wind down, Tiffany Pinkowski is just getting started. As a Cell Therapy Specialist Lead on Kite’s night shift, she ensures eligible patients receive CAR T-cell therapy on time. Her dedication reflects Kite’s commitment to capacity, speed and reliability. #mfgday25
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #ims25 on Friday 19th September for our interactive symposium exploring CAR T-cell therapy in multiple myeloma. #celltherapytalks
-
Kite, a Gilead Company
@KitePharma
Caregivers need care, too. We’re proud to partner with @AmericanCancer, @HEALCollab, @CancerSupportHQ and @NA4Caregiving to support the caregivers who stand alongside CAR T patients. Together, we're creating actionable solutions for those who give so much.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
When communities unite to drive meaningful change, we grow stronger together. Once again, we’re proud to join @BloodCancerUtd for #lightthenight, shining a light on the advances in research and treatment and the important work still ahead.
-
Kite, a Gilead Company
@KitePharma
Today, on #worldleukemiaday, we honor the courage of patients, families and caregivers who face this blood cancer with strength and resilience. At Kite, we stand with the global community in raising awareness and supporting those affected.
-
Kite, a Gilead Company
@KitePharma
The smallest details can fuel transformative breakthroughs. In this Tiny CAR T Story, we’re zooming in to explore the microscopic world of CAR T-cell therapy – an individualized medicine with curative intent. #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
This #bloodcancerawarenessmonth, we’re focused on where progress begins. Patient cells are the starting point — collected and engineered to attack cancer. Our science is the engine, turning those cells into medicine. The cure is our singular focus, every step of the way.
-
Kite, a Gilead Company
@KitePharma
More than 31,000 patients have been treated with Kite’s CAR T-cell therapies. Our global network of authorized treatment centers is supporting access for more eligible patients — closer to home and in their communities. And we’re still expanding.
-
Kite, a Gilead Company
@KitePharma
CAR T-cell therapy manufacturing at Kite is designed for capacity, speed and reliability. With the world’s largest in-house cell therapy manufacturing network, we deliver individualized therapies to authorized treatment centers for eligible patients when timing matters most.
-
Kite, a Gilead Company
@KitePharma
More than five years after CAR T-cell therapy, Kelly is celebrating graduations, weddings and everyday moments with her family.
It is an honor to share her story and drive progress in cell therapy in pursuit of potential cures.This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
#inthenews: We’ve entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics. Read more: www.kitepharma.com/news/press-releases/2025/8/kite-to-acq…
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
For Olivier Nolan-Stevaux, nature offers unexpected insights into restoring balance — in the wild and in the lab. Discover how Gilead and @KitePharma are rethinking cancer treatment through a unique scientific framework inspired by harmony in nature. gilead.inc/4mIeHFI
-
Kite, a Gilead Company
@KitePharma
We're driven to achieve potential cures with cell therapy. As we investigate expanding into earlier lines of treatment, develop our next-generation program and explore new disease areas, our commitment to advancing the power of #celltherapy remains stronger than ever.
-
Kite, a Gilead Company
@KitePharma
More than 31,000 patients worldwide have received a Kite CAR T-cell therapy. With the largest in-house cell therapy manufacturing network, we’re expanding access through speed, capacity and reliability. #celltherapy
-
Kite, a Gilead Company
@KitePharma
Stories from advocates motivate us every day to continue changing the way cancer is treated. Together with @GileadSciences, we're helping to take back possibility.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company reposted
Gilead Oncology
@GileadOncology
Cancer steals the moments that make us, but we refuse to accept that cancer can take away possibilities for the ones we love. Together with @KitePharma, we’re rethinking what’s possible to address the greatest gaps in care and helping to bring more life to people with cancer.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Meet Dr. Salyka Sengsayadeth, who oversees stem cell transplant and cellular therapy for veterans at @vatennvalley. At Kite, we're committed to expanding access to CAR T-cell therapy for more eligible patients through our global network of more than 555 treatment centers.
-
Kite, a Gilead Company
@KitePharma
#inthenews: @PennMedicine is studying how investigational uses of CAR T might one day become a therapeutic option for eligible patients with #glioblastoma. This early research offers hope for future advances in treatment. www.pennmedicine.org/news/how-future-cures-begin-as-ideas… #gbmday
-
Kite, a Gilead Company
@KitePharma
As a dedicated Quality Assurance team member within Kite's global manufacturing network, Elizabeth Pabalan focuses on delivering individualized cell therapies with urgency and precision.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Juneteenth, which commemorates the emancipation of the United States’ last enslaved African Americans, is a critical moment in our country’s history. As we honor this important day, Gilead’s Tashica Amirgholizadeh shares what the holiday means to her. #juneteenth
-
Kite, a Gilead Company
@KitePharma
We look forward to presenting our latest research and discussing advancements in lymphoma treatment at #icml2025.
Our team remains focused on advancing cell therapies and changing patients’ lives. #18icml #celltherapy -
Kite, a Gilead Company
@KitePharma
Our team attended this year’s #eha2025 where we exchanged ideas on the latest innovations in cell therapy for the treatment of blood cancer. We continue our commitment to changing the way cancer is treated by delivering innovative treatments to more patients.
-
Kite, a Gilead Company
@KitePharma
We’re excited to share that our partner @Arcellx presented new data from the pivotal Phase 2 iMMagine-1 study in relapsed/refractory multiple myeloma at #eha2025 today.
-
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #18icml on Tuesday 17th June to discuss advancements in CAR T-cell therapy for DLBCL. #celltherapytalks
-
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #eha2025 on Saturday 14th June for our interactive symposium exploring strategies to support clinicians in navigating the path to CAR T. #celltherapytalks
-
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #eha2025 on Friday 13th June for our interactive symposium exploring CAR T-cell therapy in multiple myeloma. #celltherapytalks
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
What would you tell your former self living with cancer? At #asco25, two advocates left powerful voicemails to their past selves – messages of reflection, resilience and the extraordinary fight to take back possibility in the face of cancer. Hear their inspiring stories.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Our Global Head of Research Priti Hegde shares how Kite and @GileadSciences are working together to tackle the next frontier in cell therapy: solid tumors. www.gilead.com/stories/beyond-blood-cancers-new-explorati… #asco25
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We know that inclusion can drive innovation. As we mark the start of #pridemonth, Gary Ryan, a leader in our Pride Alliance employee resource group, shares how creating space for authenticity can strengthen teams and spark bold ideas. #gileadlife
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
We’re encouraged by early results of a @PennMedicine Phase 1 clinical study of CAR T-cell therapy in recurrent GBM in @NatureMedicine. As the potential of CAR T expands beyond blood cancers, so does the hope for new options for patients. #asco25
-
Kite, a Gilead Company
@KitePharma
#kitenews: At #asco25, we shared new real-world data evaluating the safety and effectiveness of our CAR T-cell therapy in an outpatient setting for eligible patients with R/R large B-cell lymphoma. www.kitepharma.com/news/press-releases/2025/6/kite-presen…
-
Kite, a Gilead Company
@KitePharma
We're joining @GileadSciences at #asco25 to share how our singular focus on cell therapy is helping people living with cancer take back possibility.
-
Kite, a Gilead Company
@KitePharma
Today, we proudly join an international, multi-stakeholder coalition to launch #cartvision, which aims to double the number of eligible patients treated with CAR T-cell therapy by 2030. www.cartvision.com
-
Kite, a Gilead Company
@KitePharma
From new discoveries to reclaiming hope, we’re driven by a collective goal – helping to bring more life to people living with cancer. Ahead of #asco25, watch @GileadSciences and Kite leaders share what that means to them.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
At Kite, we are singularly focused on achieving cures with cell therapy. On #worldbloodcancerday, we honor the patients, caregivers and care teams at the heart of this mission and reaffirm our commitment to changing the way cancer is treated.
-
Kite, a Gilead Company
@KitePharma
We’ve been part of LABEST from the beginning. Los Angeles is our home, and we’re proud to help spotlight the innovation happening here to bring new treatments to patients. #labest2025
-
Kite, a Gilead Company
@KitePharma
#kitenews: With @GileadSciences, we’re announcing the presentation of transformative cancer research at #asco25 and #eha2025. Read more: www.kitepharma.com/news/press-releases/2025/5/gilead-and-…
-
Kite, a Gilead Company
@KitePharma
For Gaurang Patel, a passion for patient care and scientific innovation helps advance manufacturing processes that make CAR T-cell therapy possible. In recognition of #aanhpi, we’re sharing his story in our Identity + Innovation spotlight.
-
Kite, a Gilead Company
@KitePharma
We're looking forward to attending #aacr25 to discuss how we’re changing the way cancer is treated. Watch as Kite's Priti Hegde and @GileadSciences’ Jackson Egen share how we leverage research across solid tumors and hematological malignancies to discover new treatment options.
-
Kite, a Gilead Company
@KitePharma
A new docuseries from @LLSusa offers a powerful look into the lives of people transformed by CAR T-cell therapy. We’re honored to sponsor this series, which not only highlights breakthrough science but also shares stories of resilience and hope.
-
Kite, a Gilead Company
@KitePharma
As a senior distribution specialist at Kite, Mayra Escobar says the best part of her position is helping to contribute to a process that creates innovative treatments. #celltherapy
-
Kite, a Gilead Company
@KitePharma
Every day matters for blood cancer patients awaiting treatment. With the industry’s leading manufacturing turnaround time, we ensure rapid and reliable delivery of our CAR T-cell therapies, providing this potentially curative treatment to eligible patients, faster. #celltherapy
-
Kite, a Gilead Company
@KitePharma
We enjoyed discussing the transformative changes happening in the development and delivery of cell therapies that are shaping the future of blood cancer treatments at @TheEBMT annual meeting.
#ebmt25 -
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #ebmt25 on Monday 31st March for our interactive symposium exploring how to optimise outcomes in patients with R/R DLBCL.
Thank you to our panel:
@AnnalisaRugger1, @gloria_iacoboni, @CwynKate, Fabio Ciceri and Miguel-Angel Perales. -
Kite, a Gilead Company
@KitePharma
Meet Samuel Haile, Director, Cell Biology at Kite, in @GileadSciences’ latest installment of The Centrifuge Sessions. Samuel shares how his team is innovating to develop additional treatment options for people living with multiple myeloma.
#myelomaactionmonthThis media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Celebrating 10 years of Kite in the Netherlands and delivering innovative cell therapies across Europe and beyond. We're excited for the next decade of progress and impact.
-
Kite, a Gilead Company
@KitePharma
At Kite, we believe cell therapy has the ability to change the way cancer is treated. See how our process works.
-
Kite, a Gilead Company
@KitePharma
On #internationalwomensday, we’re celebrating the women at Kite and @GileadSciences who drive our work and advance our mission. Together, we’re building workplaces where everyone can make an impact, because that can help lead to a healthier world for all. #accelerateaction
-
Kite, a Gilead Company
@KitePharma
Improved treatment options for people living with multiple myeloma are long overdue. This Multiple Myeloma Awareness Month, we remain steadfast in our commitment to bringing the transformative power of CAR T-cell therapy to eligible patients in need.
#myelomaawarenessmonth -
Kite, a Gilead Company
@KitePharma
We're attending this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. We look forward to meeting with peers who share our commitment to advancing the curative potential of cell therapy treatments. #tandem25
-
Kite, a Gilead Company
@KitePharma
Thank you to Professor Roch Houot, Dr. Victoria Campbell and Dr. Abdulwahab Albabtain who spoke at our #cart25 symposium, hosted by @TheEBMT and @EHA_hematology, about insights from ASH 2024 and CAR T's curative potential in R/R lymphomas.
-
Kite, a Gilead Company
@KitePharma
Healthcare professionals, join us at #cart25 for our symposium with @TheEBMT and @EHA_hematology, exploring the curative potential of CAR T in R/R lymphomas. Hear expert insights from ASH 2024.
-
Kite, a Gilead Company
@KitePharma
We’re pleased to join and be part of @EHA_Hematology - @TheEBMT 7th EU CAR T-cell Meeting to discuss the curative potential of cell therapy for people living with certain types of blood cancers.
#cart25 -
Kite, a Gilead Company
@KitePharma
Only a few days until #cart25. Join us, @TheEBMT and @EHA_hematology at our symposium to hear leading experts discuss the curative potential of CAR T-cell therapy.
-
Kite, a Gilead Company
@KitePharma
Cancer is never just a diagnosis. It’s a story defined by unique challenges, milestones and triumphs. This #worldcancerday, we’re reaffirming our commitment to help change the way cancer is treated by seeing the person behind the diagnosis. #unitedbyunique
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We believe our people are our greatest asset, and we’re launching a new series to spotlight some of them. This #blackhistorymonth, we’re highlighting Tashica Amirgholizadeh, whose unique journey to patent law led to her making a meaningful impact at Gilead. #gileadlife
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
At Kite, we believe in the transformative power of #celltherapy. By combining leading-edge research, global in-house manufacturing and a singular focus on cell therapy—we’re helping to advance cancer treatment to offer new possibilities for patients.
-
Kite, a Gilead Company
@KitePharma
CAR T #celltherapy is changing the way cancer is treated and providing many patients with certain types of blood cancer with the potential for cure. To date, Kite cell therapies have been used to treat more than 25,000 patients worldwide.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
This has been a year of transformative progress and meaningful impact at Gilead. As 2024 comes to a close, we’re looking back on some of our exciting milestones and looking forward to helping make the world a healthier place for all people in 2025. #gileadlife
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
We’re celebrating more than 25,000 patients treated with Kite’s CAR T-cell therapies to date, but we recognize that this is just the beginning. We remain committed to expanding access and working toward ensuring every patient has a chance for a cure.
-
Kite, a Gilead Company
@KitePharma
#kitenews: We’re pleased to announce results from a five-year follow-up analysis of our CAR T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphomas, including follicular lymphoma or marginal zone lymphoma, at #ash24.
Read more: www.kitepharma.com/news/press-releases/2024/12/kites-yesc… -
Kite, a Gilead Company
@KitePharma
#kitenews: Today, we announced results from four analyses that continue to demonstrate the durability of response of Kite’s CAR T-cell therapy in patients with R/R MCL and R/R B-ALL during #ash24.
Read more: www.kitepharma.com/news/press-releases/2024/12/longest-fo… -
Kite, a Gilead Company
@KitePharma
#kitenews: We announced findings from new analyses underscoring the curative potential of our CAR T-cell therapy for people living with relapsed/refractory large B-cell lymphoma at #ash24.
Read more: www.kitepharma.com/news/press-releases/2024/12/kite-prese… -
Kite, a Gilead Company
@KitePharma
Proud to share our latest data at #ash24, highlighting the impact of CAR T-cell therapy. Every data point represents a story of resilience and hope, driving us to keep innovating for people with blood cancers worldwide.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
We’re attending #isporeurope to share our latest cell therapy research, including eight abstracts from seven countries as part of our ongoing commitment to changing the way blood cancer is treated. #celltherapy
@ISPORorg -
Kite, a Gilead Company
@KitePharma
#kitenews: We’re presenting the latest data and real-world analyses from our CAR T-cell therapy portfolio at #ash24, underscoring our commitment to patients with a spectrum of blood cancers.
Read more: www.kitepharma.com/news/press-releases/2024/11/kite-to-hi… -
Kite, a Gilead Company
@KitePharma
Our team gathered in Los Angeles for #lightthenight to celebrate the strength of the blood cancer community. Proud to support @LLSUSA as the event’s National Presenting Sponsor of Celebration and Community, holding our lanterns high to bring light to the darkness of cancer.
-
Kite, a Gilead Company
@KitePharma
Our top priority at Kite is helping to ensure that every patient who can benefit from #cartcell therapy has access to it, and our global manufacturing network is central to how we deliver CAR T to patients.
-
Kite, a Gilead Company
@KitePharma
Cancer doesn’t pause, and neither do we. On #nationalmanufacturingday, we celebrate our manufacturing and supply chain teams who work around the clock to help rapidly and reliably deliver individualized cell therapies to patients.
-
Kite, a Gilead Company
@KitePharma
#kitenews: The U.S. FDA has granted a Regenerative Medicine Advanced Therapy Designation for the evaluation of our CAR T #celltherapy as first-line treatment for high-risk large B-cell lymphoma.
Read more: www.kitepharma.com/news/company-statements/kite-receives-… -
Kite, a Gilead Company
@KitePharma
Today is #worldlymphomaawarenessday – an important opportunity to shine a light on this common form of #bloodcancer. It's vital that we come together to raise awareness of early diagnosis and treatment options that meet the needs of people living with lymphoma. #wlad
-
Kite, a Gilead Company
@KitePharma
As a quality control specialist, Angelica Quimpang helps ensure the production of our cell therapies takes place in a compliant and safe environment. The part of her job she enjoys the most is her team's shared mission to always stay focused on patients.
-
Kite, a Gilead Company
@KitePharma
On #worldleukemiaday, we honor the strength and resilience of those affected by leukemia. Branden’s story is a powerful reminder of the importance of having care partners and a support network. #wld24
-
Kite, a Gilead Company
@KitePharma
We’re proud to once again join @LLSUSA for Light The Night as the National Presenting Sponsor of Celebration & Community. Join us this fall and help bring light to the darkness of cancer.
#lightthenight -
Kite, a Gilead Company
@KitePharma
At Kite and @GileadSciences, we're dedicated to advancing research and expanding treatment options for people living with blood cancer. We’re proud to join our colleagues during #bloodcancerawarenessmonth, and all year, to raise awareness and stand with this resilient community.
-
Kite, a Gilead Company
@KitePharma
At Kite, our global, in-house manufacturing network is central to how we develop and deliver our cell therapies.
-
Kite, a Gilead Company
@KitePharma
At Kite, our sole focus is on the research, development and delivery of #cartcell therapy because our goal is to bring these innovative treatments to as many eligible patients as possible.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
#gileadnews: Read the press release to learn more about our financial results from last quarter. gilead.inc/46GkIvL
-
Kite, a Gilead Company
@KitePharma
William served his country as a submarine sailor, where he was part of a team. After he retired from service, he was diagnosed with #bloodcancer. Again, he needed a team and found one at the VA Tennessee Valley Healthcare System Medical Center.
-
Kite, a Gilead Company
@KitePharma
We’re proud to be part of @GileadSciences.
Gilead Sciences
@GileadSciences
For the third year in a row, we’ve been recognized as one of @Forbes #bestemployersforwomen. Women at Gilead are vital to our success — driving innovation and helping us further our mission to create a healthier world for all people.
-
Kite, a Gilead Company
@KitePharma
The team at Kite has been recognized again this year by @SantaMonicaCity for our commuter programs that help reduce emissions and congestion. Our headquarters and our Research, Development and Manufacturing Center received platinum Go Santa Monica (GoSaMo) Achievement Awards.
-
Kite, a Gilead Company
@KitePharma
We enjoyed meeting with our peers at the Singapore Cell & Gene Therapy Pan Asia Summit. Thank you to everyone who participated and shared the latest advancements in innovative treatments.
-
Kite, a Gilead Company
@KitePharma
.@GileadSciences and Kite received International and Regional Awards from the Association of Energy Engineers for outstanding contributions to the field of energy and sustainability. Our passion for creating a healthier world drives us to be responsible corporate citizens.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
During #pridemonth, Gilead and @KitePharma employees, families and friends proudly participated in the @SFPride and WeHo Pride parades to celebrate the LGBTQ+ community, embodying our theme of “live, love, liberate” -- an anthem of equality and inclusion for all.
-
Kite, a Gilead Company
@KitePharma
Thank you to the @Surfrider Foundation for hosting us for a beach cleanup day in Santa Monica. Kite teammates volunteered as part of our Month of Service.
-
Kite, a Gilead Company
@KitePharma
.@GileadSciences and Kite teammates shared what #juneteenth means to them and gathered for a flag raising ceremony, emphasizing the significance of this important day in American history. The event was an opportunity to reflect and recognize Juneteenth.
Gilead Sciences
@GileadSciences
Remi Murphy, a member of the Gilead Leadership Organization of Black Employees (GLOBE) Employee Resource Group, shares what #juneteenth means to her and the significance of Gilead’s annual flag raising. Hear her perspective about a day that symbolizes hope and progress.
-
Kite, a Gilead Company
@KitePharma
We enjoyed being part of #eha2024 and discussing the latest in research and care for people living with blood cancer. We are proud to be part of the #hematology community and remain committed to changing the future of blood cancer treatment.
-
Kite, a Gilead Company
@KitePharma
At #eha2024, we presented new data on how we can bring CAR T-cell therapies closer to home to reach more eligible people with blood cancer. Kite’s Head of Medical Affairs Ibrahim Elhoussieny, MD, highlights the feasibility of making outpatient CAR T a reality.
-
Kite, a Gilead Company
@KitePharma
#kitenews: At #eha2024, we announced results from three new analyses for #cartcell therapy in R/R large B-cell lymphoma, including both new clinical research and real-world evidence highlighting manufacturing and product characteristics.
Read more: www.kitepharma.com/news/press-releases/2024/6/new-kite-cl… -
Kite, a Gilead Company
@KitePharma
CAR T-cell therapies are changing the way cancer is treated. Ahead of #eha2024, Kite’s Global Head of Medical Affairs Ibrahim Elhoussieny, MD, discusses how we can reach more eligible patients through the manufacturing of these highly individualized treatments.
-
Kite, a Gilead Company
@KitePharma
A big thanks to @ASCO for an amazing annual meeting. It was great connecting with the oncology community and sharing updates from our #celltherapy portfolio. #asco24
-
Kite, a Gilead Company
@KitePharma
.@GileadSciences and Kite teams raised #pridemonth flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally. Our commitment to inclusion and diversity is vital to our mission and will help us create a healthier world for all people.
-
Kite, a Gilead Company
@KitePharma
#kitenews: We’re announcing updated, four-year overall survival data on our #cartcell therapy in adult patients with R/R B-cell acute lymphoblastic leukemia. The results were presented today at #asco24.
Read more: www.kitepharma.com/news/press-releases/2024/6/kites-tecar… -
Kite, a Gilead Company
@KitePharma
#kitenews: At #asco24, we’re announcing new data on #cartcell therapy in patients living with R/R central nervous system lymphoma – an aggressive and rare form of non-Hodgkin lymphoma.
Read more: www.kitepharma.com/news/press-releases/2024/6/encouraging… -
Kite, a Gilead Company
@KitePharma
#kitenews: We're attending #eha2024 where we will present 12 abstracts featuring new data from our industry-leading portfolio, including highlighting the manufacturing and delivery of CAR T-cell therapy.
Read more: www.kitepharma.com/news/press-releases/2024/5/kite-data-a… -
Kite, a Gilead Company
@KitePharma
#kitenews: Today we announced with @Arcellx, the Phase 3 clinical trial design for a #cartcell therapy in R/R multiple myeloma. Kite expects to start the trial in the second half of the year and will manufacture the therapy.
Read more: www.kitepharma.com/news/press-releases/2024/5/kite-and-ar… -
Kite, a Gilead Company
@KitePharma
#kitenews: We’re joining @GileadOncology at #asco24 to present new data that will showcase our ongoing commitment to help transform how cancer is treated through differentiated approaches.
Read more: www.kitepharma.com/news/press-releases/2024/5/gilead-and-… -
Kite, a Gilead Company
@KitePharma
For #aapiheritagemonth, we celebrate the contributions of Asian Americans and Pacific Islanders. Mehrshid Alai-Safar, VP of Regulatory Affairs at Kite and member of GAIN (Gilead Asian Interest Network), shares her perspective on why it is important to honor cultural heritage.
-
Kite, a Gilead Company
@KitePharma
Thank you to @theEBMT for hosting an engaging annual meeting last week. Our team found connecting with the #celltherapy community, including discussing the latest advancements and how innovative therapies are changing the way blood cancers are treated, extremely valuable. #ebmt24
-
Kite, a Gilead Company
@KitePharma
We’re proud to be part of @GileadSciences. #gileadforgood
Gilead Sciences
@GileadSciences
Through innovation, growth and impact, our vision is to create a healthier world for all people. Read our 2023 ESG Impact Report and see how we’re driving positive change through every aspect of our business. www.gilead.com #gileadforgood
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
We are in Glasgow for @theEBMT 50th Annual Meeting and to recognize five decades of scientific exchange and innovation from the #celltherapy community. We look forward to discussions on how we can change the future for people living with blood cancers. #ebmt24
-
Kite, a Gilead Company
@KitePharma
As the only company dedicated solely to the research, development and manufacturing of #celltherapy, we are pleased to announce we are approved to make our treatment available in Brazil, Saudi Arabia and Singapore.
-
Kite, a Gilead Company
@KitePharma
Kite has embedded sustainability into our culture and global manufacturing operations. Our collaboration with @SustainabltyMag shares how we ensure we are having a positive impact on the communities where we live and work.
Read more: sustainabilitymag.com/magazine/sustainability-magazine-ma… -
Kite, a Gilead Company
@KitePharma
We’re looking forward to attending the 6th European CAR T-cell Meeting where the newest advancements in #celltherapy are discussed, including our research. #cart24
-
Kite, a Gilead Company
@KitePharma
#inthenews: We’re proud to be part of @GileadSciences.
Gilead Sciences
@GileadSciences
#gileadnews: Our Q4 and Full Year 2023 Financial Results are now available. Read the press release: gilead.inc/3HNMQl9
#earnings -
Kite, a Gilead Company
@KitePharma
#kitenews: The U.S. FDA has approved a manufacturing process change resulting in a shorter manufacturing time for our #celltherapy, which is anticipated to reduce median turnaround time from 16 to 14 days in the United States.
Read more: www.kitepharma.com/news/press-releases/2024/1/kite-receiv… -
Kite, a Gilead Company
@KitePharma
#kitenews: The U.S. FDA has approved a label update for our CAR T-cell therapy to include overall survival data from a primary analysis of our therapy versus standard of care as second-line treatment with curative intent.
Read more: www.kitepharma.com/news/press-releases/2023/12/us-fda-app… -
Kite, a Gilead Company
@KitePharma
#kitenews: Today, we shared analyses of three #cartcell therapy studies that explore curative potential for patients living with several sub-types of R/R non-Hodgkin lymphoma at @ASH_hematology's Annual Meeting. #ash23
Read more: www.kitepharma.com/news/press-releases/2023/12/analyses-o… -
Kite, a Gilead Company
@KitePharma
#kitenews: Today, we announced four new long-term follow-up analyses that support the use of #celltherapy for the treatment of R/R mantle cell lymphoma and R/R adult B-cell precursor acute lymphoblastic leukemia at #ash23.
Read more: www.kitepharma.com/news/press-releases/2023/12/new-analys… -
Kite, a Gilead Company
@KitePharma
#kitenews: Announcing new findings from a follow-up analysis of #cartcell therapy from the first study of its kind in patients with high-risk, large B-cell lymphoma. The study’s results were presented at #ash23 .
Read more: www.kitepharma.com/news/press-releases/2023/12/long-term-… -
Kite, a Gilead Company
@KitePharma
We’re pleased to share that our partner @Arcellx will present new data in relapsed/refractory multiple myeloma at @ASH_hematology's Annual Meeting. #ash23
-
Kite, a Gilead Company
@KitePharma
Ahead of #ash23, hear from Kite’s Global Head of Clinical Development Frank Neumann, MD, PhD, and Global Head of Research Priti Hegde, PhD, on how far the science of cell therapy has progressed and where it is headed.
-
Kite, a Gilead Company
@KitePharma
#kitenews: Together with @GileadOncology, we’ll share 29 presentations across our blood cancer portfolio at @ASH_Hematology’s Annual Meeting. #ash23
Read more: www.kitepharma.com/news/press-releases/2023/11/gilead-and… -
Kite, a Gilead Company
@KitePharma
#kitenews: Today, we announced that we’ve entered into a research collaboration and license agreement with @EpicBiotech using their proprietary gene regulation platform to develop next-generation cancer cell therapies.
Learn more: www.kitepharma.com/news/press-releases/2023/10/kite-and-e… #celltherapy -
Kite, a Gilead Company
@KitePharma
#kitenews: Together with @GileadOncology, we will present data from our oncology portfolio at #esmo23, including new #celltherapy research. @MyESMO
Read more: www.kitepharma.com/news/press-releases/2023/10/gilead-and… -
Kite, a Gilead Company
@KitePharma
This week, we announced Priti Hegde, PhD, will join Kite as Senior Vice President and Global Head of Research. www.kitepharma.com/news/company-statements/kite-appoints-…
-
Kite, a Gilead Company
@KitePharma
Today, we announced full results from a Phase 2 study led by the French collaborative group LYSA/LYSARC for CAR T-cell therapy as a second-line treatment for transplant ineligible patients with large B-cell #lymphoma, published in @NatureMedicine
-
Kite, a Gilead Company reposted
Gilead Oncology
@GileadOncology
Today kicks off #bloodcancerawarenessmonth. Gilead and @KitePharma proudly join the efforts of the many individuals and organizations raising disease awareness, funding research and uplifting the blood cancer community.
-
Kite, a Gilead Company
@KitePharma
Advances in #celltherapy offer the potential for more treatment options for patients battling cancer. This is our sole focus – researching, manufacturing, and commercializing innovative treatment options to reach as many eligible patients as possible who may benefit from them.
-
Kite, a Gilead Company
@KitePharma
We’re proud to join @GileadOncology to serve as the National Presenting Sponsor of Celebration and Community for #lightthenight 2023. Together with the @LLSusa, we’re shining a light on the darkness of cancer. Here’s a look at last year’s event.
-
Kite, a Gilead Company
@KitePharma
Each year, Kite welcomes service members into our fellowship program created for #veterans. Through the program, veterans have the opportunity to learn about cell therapy development and manufacturing, while bringing their leadership skills to the table.
-
Kite, a Gilead Company
@KitePharma
Unlike traditional pharmaceuticals, #cartcell therapies are individually made from a patient’s own white blood cells and given as a one-time individual dose. Our teams are dedicated to ensuring the highest quality standards throughout the entire manufacturing process.
-
Kite, a Gilead Company
@KitePharma
Our #cartcell therapy manufacturing is personal because each batch we create is made for a specific patient using their own white blood cells. This is why we’re dedicated to the highest quality standards every step of the way.
-
Kite, a Gilead Company
@KitePharma
#news: @GileadSciences and Kite announce the completion of the Marketing Authorization transfer to commercialize our #cartcell therapy in Japan. We will leverage our commercial leadership and global cell therapy manufacturing network to meet increasing patient demand.
-
Kite, a Gilead Company
@KitePharma
At Kite, our goal is to reach more eligible patients with #cartcell therapy. This is why we are committed to advancing our research for the treatment of blood cancers like large B-cell lymphoma (LBCL).
-
Kite, a Gilead Company
@KitePharma
We were honored to join the hematology community at #eha2023 and discuss our commitment to changing the lives of people living with #bloodcancer.
-
Kite, a Gilead Company
@KitePharma
We’re focused on changing the future of cancer treatment for people living with difficult-to-treat blood cancers. Join us at #eha2023 to hear the latest updates from our #celltherapy portfolio.
-
Kite, a Gilead Company
@KitePharma
What drives our innovation? The potential to help people live longer and fuller lives. Hear from our Global Head of Clinical Development Frank Neumann, MD, PhD, as he shares the significance of overall survival data in cancer research. #asco23
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced findings from the largest real-world analysis to date of #cartcell therapy in patients with relapsed/refractory mantle cell lymphoma. #asco23
-
Kite, a Gilead Company
@KitePharma
#news: Announcing detailed results from the overall survival analysis of the landmark Phase 3 study of #cartcell therapy compared with historical standard of care as initial treatment for relapsed/refractory large B-cell lymphoma. #asco23
-
Kite, a Gilead Company reposted
Gilead Oncology
@GileadOncology
Discover how we’re making a difference in some of the most difficult-to-treat cancers. #asco23
-
Kite, a Gilead Company
@KitePharma
Gilead and Kite have authorized more than 350 independent treatment
centers where patients can receive #cartcell therapy across the globe, including more than 125 in the U.S. -
Kite, a Gilead Company
@KitePharma
Together with @GileadOncology, we will present 17 abstracts from our industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 @EHA_Hematology Annual Congress. #eha2023
-
Kite, a Gilead Company
@KitePharma
Proud to be part of @GileadSciences.
Gilead Sciences
@GileadSciences
We’re honored to be ranked on @Newsweek's just-released list of the 2023 Top 100 Global Most Loved Workplaces – a testament to our employees’ positive vision of Gilead’s future, a culture of inclusion and integrity, company benefits and values. #mostlovedworkplace
-
Kite, a Gilead Company
@KitePharma
We’re excited to join the Los Angeles life sciences community at the LA Bioscience Ecosystem Summit 2023 (LABEST) to discuss the latest technology and innovation in LA biopharma with @UCLATDG. #labest2023
-
Kite, a Gilead Company
@KitePharma
Our team at Kite is focused on innovation and research to ensure that every eligible patient who can benefit from #cart has access to this therapy.
-
Kite, a Gilead Company
@KitePharma
Kite has the largest, dedicated, in-house #celltherapy manufacturing network that spans process development, vector manufacturing, clinical trial production and commercial product manufacturing.
-
Kite, a Gilead Company
@KitePharma
Together with @GileadOncology, we will present 30 abstracts at the 2023 American Society of Clinical Oncology (@ASCO) Annual Meeting, including overall survival data from our landmark Phase 3 study of #cartcell therapy in relapsed/refractory large B-cell lymphoma. #asco23
-
Kite, a Gilead Company
@KitePharma
We’re pleased to welcome Cindy Perettie as the new Executive Vice President of Kite. Read the full announcement: www.kitepharma.com/news/press-releases/2023/5/gilead-appo…
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Today, we’re pleased to announce Cindy Perettie as the new Executive Vice President of Kite and a member of Gilead’s senior leadership team. gilead.inc/3WdGlhJ
-
Kite, a Gilead Company
@KitePharma
Thank you for this recognition @MDTechCouncil!
Maryland Tech Council
@MDTechCouncil
Life Sciences Company of the Year award sponsored by @BDO_USA is presented to @KitePharma! Congratulations! #mtciac
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
In our first quarter, we built on the momentum we saw in 2022 and made important progress in our work to make the world a healthier place for all people. We look forward to growth and continued advancements across HIV, oncology and our other therapeutic areas. #earnings
-
Kite, a Gilead Company
@KitePharma
We were pleased to join the global blood cancer community at @theEBMT’s annual meeting. Thank you to everyone who participated and shared the latest advances in blood cancer research. #ebmt23
-
Kite, a Gilead Company
@KitePharma
We look forward to @theEBMT to join world-leading researchers and healthcare professionals to share the latest #celltherapy research for difficult-to-treat blood cancers. #ebmt23
-
Kite, a Gilead Company
@KitePharma
Proud to be part of @GileadSciences and share the launch of Gilead’s inaugural ESG Impact Report. At Kite, we strive to continually improve our environmental footprint, foster an inclusive workplace and have an overall positive impact in the communities we serve.
Gilead Sciences
@GileadSciences
Today, we launched our inaugural ESG Impact Report. Learn how we’re advancing our mission to create a healthier world while benefiting our people, the communities we support and our planet.
-
Kite, a Gilead Company
@KitePharma
CAR T technology is changing the way #cancer is treated by using the power of a person’s own immune system. A CAR, or chimeric antigen receptor, is a gene added to a T cell allowing it to recognize and attack certain cancer cells.
-
Kite, a Gilead Company
@KitePharma
This #womenshistorymonth, we recognize the significant contributions from women in STEM, paving the way for the latest advancements in science and research.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.
-
Kite, a Gilead Company
@KitePharma
March is #myelomaawarenessmonth. We’re dedicated to advancing CAR T-cell therapy research to reach more patients living with difficult-to-treat blood cancers, like myeloma.
-
Kite, a Gilead Company reposted
Tmunity Therapeutics
@TmunityTx
Tmunity has been acquired by Kite, a Gilead Company. Follow @KitePharma for updates.
-
Kite, a Gilead Company
@KitePharma
#news: Announcing the completion of the previously announced transaction to acquire @TmunityTx, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced follow-up results from a pivotal study of #cartcell therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia at the @EHA_Hematology @TheEBMT 5th European CAR T-cell Meeting. #cart23
-
Kite, a Gilead Company
@KitePharma
#news: Kite and @Arcellx announce the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize a CAR T-cell therapy candidate in relapsed or refractory multiple myeloma.
-
Kite, a Gilead Company
@KitePharma
#news: Announcing an expansion to our cell therapy operations in Frederick, Maryland with a new, centralized raw materials warehouse that will serve Kite’s global manufacturing network, bring 100 additional jobs to the area and deepen the company’s investment in the community.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved our CAR T-cell therapy for second-line treatment of adult patients with relapsed/refractory large B-cell lymphoma.
-
Kite, a Gilead Company
@KitePharma
#news: Announcing our intent to acquire @TmunityTx, a clinical-stage, private biotech focused on next-generation CAR T, adding additional pipeline assets, platform capabilities and a strategic research and licensing agreement with @PennMedicine to Kite’s portfolio.
-
Kite, a Gilead Company
@KitePharma
Sharing follow-up data from our studies of #cartcell therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory mantle cell lymphoma. #ash22
-
Kite, a Gilead Company
@KitePharma
Today at #ash22, we’re presenting follow-up data from our studies of #cartcell therapy in adult patients with relapsed/refractory indolent non-Hodgkin lymphoma and patients with relapsed/refractory large B-cell lymphoma.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced new findings from our pivotal study of #cartcell therapy versus standard-of-care in patients with relapsed/refractory large B-cell lymphoma. #ash22
-
Kite, a Gilead Company
@KitePharma
Today, we shared results from one of the largest real-world analyses of CAR T-cell therapy assessing the impact of time from leukapheresis to infusion in adult patients with relapsed/refractory large B-cell lymphoma. #ash22
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced a strategic collaboration with @Arcellx to co-develop and co-commercialize a CAR T-cell therapy candidate in relapsed or refractory multiple myeloma.
-
Kite, a Gilead Company
@KitePharma
#news: Kite and Daiichi Sankyo announce revision to partnership agreement in Japan – marketing authorization will be transferred to Gilead subsidiary in Japan next year. Kite’s manufacturing site in California has received Japanese regulatory approval to produce CAR T for Japan.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Next month at #ash22, we’ll be sharing data from 30 abstracts alongside @KitePharma. See a preview of our #bloodcancer research at this year’s meeting, including updates in myelodysplastic syndromes #mds, acute myeloid leukemia #aml and large B-cell lymphoma #lbcl.
-
Kite, a Gilead Company
@KitePharma
We’re highlighting our latest innovations in cell therapy at this year’s @ASH_hematology annual meeting. Alongside @GileadOncology, we will present data from 30 abstracts, including seven oral presentations in large B-cell lymphoma. #ash22
-
Kite, a Gilead Company
@KitePharma
#cartcell therapy is a one-time infusion individualized for each patient. Supporting patients through the cell therapy journey is central to our work at Kite.
-
Kite, a Gilead Company
@KitePharma
As one of the first #cartcell therapy companies, we are proud to have the largest, dedicated in-house cell therapy #manufacturing network in the world to deliver our revolutionary therapies to as many eligible patients as possible.
-
Kite, a Gilead Company
@KitePharma
Let’s bring the light to the darkness of #bloodcancer as we proudly join @LLSusa as the @LightheNight National Presenting Sponsor of Celebration & Community for 2022 & 2023. Together, we’re committed to fighting blood cancer and finding potential cures. #lightthenight
-
Kite, a Gilead Company
@KitePharma
Michael, his family, and his oncologist approached the relapse of his non-Hodgkin lymphoma as a team. They were hopeful when he was selected to participate in a #cartcell therapy clinical trial.
-
Kite, a Gilead Company
@KitePharma
Today we announced that we’ve entered into a license agreement with Refuge Biotechnologies, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize their proprietary gene expression platform to develop potential treatments for blood cancers.
-
Kite, a Gilead Company
@KitePharma
Our #cartcell therapy technology uses the power of the immune system to target and attack cancer cells. Learn how our innovative science works.
-
Kite, a Gilead Company
@KitePharma
We are pleased to announce the @EU_Commission has granted approval for our #cartcell therapy for adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who do not respond to first-line treatment.
-
Kite, a Gilead Company
@KitePharma
Innovation in cell therapy is closely tied to innovation in manufacturing. As the largest, dedicated in-house #celltherapy manufacturing network in the world, we are proud to celebrate #nationalmanufacturingday.
-
Kite, a Gilead Company
@KitePharma
Congratulations to Kite CEO Christi Shaw on her inclusion in the 2022 @Forbes 50 over 50 Entrepreneurs List! This group of leaders has been recognized for the innovative ways they’re disrupting their fields, ranging from manufacturing to technology to healthcare.
-
Kite, a Gilead Company
@KitePharma
Acute lymphoblastic leukemia (ALL) starts in the bone marrow and occurs when #leukemia cells increase. If left untreated, it can progress quickly.
-
Kite, a Gilead Company
@KitePharma
We are pleased to announce the @US_FDA has approved our viral vector manufacturing facility in Southern California for commercial production, further strengthening Kite's global #celltherapy manufacturing network.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Nadia Wajid shares what attracted her to @KitePharma and why keeping employees energized about the company's work for people living with blood cancer feels personally meaningful to her. #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
Today we announced the @US_FDA has granted Orphan Drug Designation for our #cartcell therapy candidate for the treatment of acute myeloid leukemia.
-
Kite, a Gilead Company
@KitePharma
Empowering patients and caregivers to navigate a blood cancer diagnosis with their healthcare team is critical, and it starts with education. Thank you to Crissy Kus, nurse educator, @LLSusa, for joining us this week for an educational discussion during #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
We are dedicated to advancing #cartcell therapy to bring hope to more patients living with difficult-to-treat blood cancers. #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw and Lymphoma Coalition (@knowyournodes) CEO Lorna Warwick share why it’s so important for patients and caregivers to understand all their treatment options after a blood cancer diagnosis. #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
We are driven by our singular focus of cell therapy to treat and potentially cure difficult-to-treat blood cancers for people like Chuck, diagnosed with follicular lymphoma. Listen as he describes his #cartcell therapy experience.
-
Kite, a Gilead Company
@KitePharma
This #bloodcancerawarenessmonth, we acknowledge the strength and resilience of the blood cancer community as we work to advance innovative therapies for more people with difficult-to-treat blood cancers. x.com/i/events/1572248476830035969
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Former oncology nurse Amy Dembeck, Associate Director, Public Affairs at Kite, lives with follicular lymphoma and knows how important advocacy is to raising awareness and helping patients. Hear her story. #bloodcancerawarenessmonth #fightbloodcancer #meanstome
-
Kite, a Gilead Company
@KitePharma
We are pleased to announce @EMA_News Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for our #cartcell therapy for the treatment of adult patients with second-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
-
Kite, a Gilead Company
@KitePharma
Tonight we join buildings and landmarks around the world in shining a light on lymphoma. #lightitred #wlad2022 #bloodcancerawarenessmonth
-
Kite, a Gilead Company
@KitePharma
Today, Kite employees across the globe recognize World Lymphoma Awareness Day and proudly #lightitred for lymphoma awareness. #wlad2022 @lymphoma
-
Kite, a Gilead Company
@KitePharma
When Kelly’s non-Hodgkin lymphoma didn’t respond to initial lines of therapy, her doctor recommended #cartcell therapy as a potential treatment option. “No matter how bad it gets don’t ever give up hope,” says Kelly.
-
Kite, a Gilead Company
@KitePharma
Today we announced the European Commission has granted Marketing Authorization for our #cartcell therapy for the treatment of adult patients (26+) with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
-
Kite, a Gilead Company
@KitePharma
In recognition of #worldleukemiaday, we join the global mission to bring hope to more people like Branden through the potential of #cartcell therapy.
-
Kite, a Gilead Company
@KitePharma
September is #bloodcancerawarenessmonth. We stand with @GileadSciences and @GileadOncology as we work to bring innovative therapies to more people living with difficult-to-treat blood cancers.
-
Kite, a Gilead Company
@KitePharma
Today we announced the expansion of Kite’s global cell therapy business with the launch of operations in Brazil, Singapore and Saudi Arabia.
-
Kite, a Gilead Company
@KitePharma
Kite is proud to have more than 270 authorized treatment centers where patients can receive CAR T-cell therapy across the globe, including more than 110 in the U.S.
-
Kite, a Gilead Company
@KitePharma
Kite’s industry-leading CAR T-cell therapies use a person’s own immune system – their white blood cells – to target and attack certain blood cancers. We develop our individualized therapies for one person at a time.
-
Kite, a Gilead Company
@KitePharma
Kite cell therapy specialists, like Niemel, play a critical role in manufacturing individualized therapies for people with difficult-to-treat blood cancers. Our team works diligently to ensure patients’ cells are handled with the utmost precision and care.
-
Kite, a Gilead Company
@KitePharma
CAR T-cell therapy uses the power of a person’s own immune system – their white blood cells – to help people living with difficult-to-treat cancers. At Kite, our mission is singularly focused on cell therapy to treat and potentially cure cancer.
-
Kite, a Gilead Company
@KitePharma
Today we announced Chris McDonald has been appointed Kite’s Global Head of Technical Operations.
-
Kite, a Gilead Company
@KitePharma
When Eleonora’s non-Hodgkin lymphoma didn't respond to initial lines of treatment, she decided to explore CAR T-cell therapy. “A small voice arose inside of me that said do not give up," she remembers.
-
Kite, a Gilead Company
@KitePharma
As part of our ongoing commitment to #sustainability, Kite is now 100% electricity carbon net zero. Through our work with local utilities and our investment in renewable energy credits, we are proud to achieve a neutral electricity carbon footprint.
-
Kite, a Gilead Company
@KitePharma
We’re proud to have more than 270 authorized treatment centers around the globe where patients can receive #cartcell therapy, including more than 110 in the U.S.
-
Kite, a Gilead Company
@KitePharma
We are pleased to announce @EMA_News Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for our CAR T-cell therapy for the treatment of adult patients (26+) with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
-
Kite, a Gilead Company
@KitePharma
Our industry-leading cell therapy technology uses the power of a person’s own immune system – their white blood cells – to target and attack their cancer cells.
-
Kite, a Gilead Company
@KitePharma
After discussing treatment options with his doctor, Chuck decided to try #cartcell therapy to treat his relapsed follicular lymphoma. Today, he’s thankful for being able to experience more of life with his two young daughters.
-
Kite, a Gilead Company
@KitePharma
At Kite, we’re singularly focused on cell therapy to treat and potentially cure cancer. Our team is advancing #cartcell therapy technology to help people living with difficult-to-treat blood cancers.
-
Kite, a Gilead Company
@KitePharma
Dedicated cell therapy specialists, like Katie, come to work every day to change the future of cancer treatment. Our team is driven by our mission to bring #cartcell therapy to more patients with difficult-to-treat cancers.
-
Kite, a Gilead Company
@KitePharma
Our industry-leading CAR T-cell therapy technology uses the power of a person’s own immune system to target and attack certain types of blood cancer. It’s our goal to bring #celltherapy to as many eligible patients as possible.
-
Kite, a Gilead Company
@KitePharma
Our #cartcell therapy technology uses the power of a person’s own immune system by engineering T cells to target and attack certain types of cancer cells.
-
Kite, a Gilead Company
@KitePharma
Today we announced that the European Commission has granted marketing authorization for our CAR T-cell therapy for the treatment of adult patients with advanced relapsed/refractory follicular lymphoma.
-
Kite, a Gilead Company
@KitePharma
When developing #cartcell therapies using a patient’s own white blood cells, manufacturing becomes personal to employees like Alexis. At Kite, we’re committed to providing potentially life-saving CAR T-cell therapies to patients who need it most.
-
Kite, a Gilead Company
@KitePharma
As we join in celebrating @GileadSciences' 35th anniversary, we are proud to be working together to change the future of cancer treatment.
Gilead Sciences
@GileadSciences
Over Gilead’s 35-year history, bold ambitions were set and achieved in the company’s fight against devastating diseases. On our anniversary, watch a video featuring our commitment to help make the world a healthier place for all people. #35yearsofgilead
-
Kite, a Gilead Company
@KitePharma
Watch how a person’s own T cells are engineered to recognize targets on the surface of cancer cells. Once infused back into the patient, CAR T cells can multiply to target and attack cancer cells. This is #cartcell therapy.
-
Kite, a Gilead Company
@KitePharma
Kite employees joined our Gilead Leadership Organization of Black Employees (GLOBE) employee resource group ahead of #juneteenth to recognize the achievements, resilience and historic contributions of Black Americans, and discuss the work ahead of us to advance racial #equity
-
Kite, a Gilead Company
@KitePharma
When his lymphoma returned after multiple rounds of treatment, CAR T-cell therapy brought hope to Chip and his wife when they needed it most.
-
Kite, a Gilead Company
@KitePharma
As we continue to research #celltherapy across hematologic malignancies, we thank #eha2022 for the opportunity to share our data with the scientific community. We are proud to stand together to expand treatment options for people living with #bloodcancers.
-
Kite, a Gilead Company
@KitePharma
Many patients with the most difficult-to-treat #bloodcancers face the greatest gaps in care. Join us at #eha2022, where we will present new data for our #celltherapy portfolio across several hematologic malignancies.
-
Kite, a Gilead Company reposted
Gilead Oncology
@GileadOncology
Today is the final day of #asco22. Here you'll hear from @KitePharma’s Alex Avila, who reflects on the important role this meeting plays in advancing CAR T-cell therapy for people living with certain blood cancers. #meanstome
-
Kite, a Gilead Company
@KitePharma
Today we celebrate cancer survivors and their loved ones, whose resilience inspires us as we work to help more people living with cancer overcome this disease. #ncsd2022
-
Kite, a Gilead Company
@KitePharma
We are excited to share long-term follow-up data from two pivotal studies of #cartcell therapy in relapsed or refractory mantle cell lymphoma and adult acute lymphoblastic leukemia. #asco22
-
Kite, a Gilead Company
@KitePharma
At #asco22, we’re sharing additional analyses of #cartcell therapy as a second-line treatment for relapsed or refractory large B-cell lymphoma patients aged 65 or older.
-
Kite, a Gilead Company
@KitePharma
For Day 2 of #asco22, we’re presenting our latest advances in #cartcell therapy research for lymphoma and leukemia.
-
Kite, a Gilead Company
@KitePharma
News from #asco22: Today we announced findings from our real-world evidence analysis by race and ethnicity for patients with relapsed or refractory large B-cell lymphoma (LBCL).
-
Kite, a Gilead Company
@KitePharma
After receiving a large B-cell lymphoma diagnosis, Julie went through multiple rounds of chemotherapy. When the cancer returned, her doctor discussed #cartcell therapy as a potential treatment option, bringing hope to her and her family.
-
Kite, a Gilead Company
@KitePharma
Join us during #asco22 to learn more about our advances in #cartcell therapy to support new innovations in cancer care.
-
Kite, a Gilead Company
@KitePharma
We're excited to join @GileadOncology at #asc022 this week and share the latest advances in cell therapy.
Gilead Oncology
@GileadOncology
We’re at #asco22 this week to present our latest research and advancements in supporting new innovations in #cancer care. Our ambition is to help bring more life to people with overlooked, underserved and difficult-to-treat cancers.
-
Kite, a Gilead Company
@KitePharma
Our #cartcell therapy technology uses the power of a person’s own immune system to fight blood #cancer. It works by engineering a patient’s T cells to target and attack certain types of cancer cells.
-
Kite, a Gilead Company
@KitePharma
“Our number one goal is to take the proven science of CAR T-cell therapy and make sure it gets to patients across the globe, sooner,” says Kite CEO Christi Shaw during the Meet the Leaders in the Business of Life Sciences panel @UCLATDG #labest2022
-
Kite, a Gilead Company
@KitePharma
Kite team members joined fellow life sciences leaders (and future leaders) at #labest2022 today. We are proud to be part of the exciting growth of the Los Angeles bioscience ecosystem! @UCLATDG
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Daan Koper leads a team that supports the production of @KitePharma’s cell therapies at our facility in the Netherlands. Learn how he’s grown professionally while playing a key role in some of the most innovative manufacturing in biopharma. #gileadlife gilead.inc/3lIIEYN
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw joined @CliftonLeaf at the Personalized Medicine Coalition’s Annual #personalizedmedicine Conference to discuss Kite's focus on ensuring CAR T-cell therapy reaches as many eligible patients as possible, as early as possible. #permedconf
-
Kite, a Gilead Company
@KitePharma
We’re proud to join the Los Angeles life sciences community at the LA Bioscience Ecosystem Summit 2022 (LABEST) next week to help shape the future of LA biopharma with @UCLATDG. #labest2022
-
Kite, a Gilead Company
@KitePharma
Thank you @BioBuzzMaryland for highlighting Kite's commitment to diversity, equity and inclusion and how it helped shape the growth of our cell therapy manufacturing facility in Frederick, MD!
BioBuzz
@BioBuzzNetworks
Diversity, equity, & inclusion are values shared by the team at @kitepharma's Frederick manufacturing site. Learn how the company’s DE&I efforts are positively impacting underrepresented #biotech employees: biobuzz.io/news/diversity-equity-inclusion-at-kite-a-key-…
#diversity #inclusion #equity #dei -
Kite, a Gilead Company
@KitePharma
We’re proud to join @GileadSciences at #asco22 to share how our industry-leading #cartcell therapy portfolio is changing the way cancer is treated.
Gilead Sciences
@GileadSciences
At #asco2022, we’re showcasing Gilead and @KitePharma’s diverse oncology pipeline. Our data presentations reinforce the potential of our transformative science across multiple cancers.
-
Kite, a Gilead Company
@KitePharma
Warner Biddle, Kite Global Head of Commercial, joined @ftlive at the US Pharma and Biotech Summit today to discuss the importance of value and innovation in market access, and how stakeholders can work together to bring #cartcell therapies to more eligible patients. #ftpharma
Financial Times Live
@ftlive
The pandemic forced the pharma industry & regulators to re-think how new drugs should be brought to market in America & globally. Our next #ftpharma panel explore with @kiranstacey the future of market access in the US.
@KitePharma @icer_review @UPMCEnterprises @TakedaOncology -
Kite, a Gilead Company
@KitePharma
This #nationalnursesweek, we honor the dedication and compassion of oncology nurses who guide patients and their loved ones through #cartcell therapy. Thank you for everything you do.
-
Kite, a Gilead Company
@KitePharma
After receiving a non-Hodgkin lymphoma diagnosis and multiple lines of treatment, Emily was determined to be there for her family. This #mothersday, we celebrate moms everywhere who balance motherhood and a cancer diagnosis.
-
Kite, a Gilead Company
@KitePharma
This National Cancer Research Month, we thank the scientists and researchers who advance the science of #cartcell therapy in the pursuit of cures for cancers. #ncrm22
-
Kite, a Gilead Company
@KitePharma
Our new state-of-the-art #celltherapy manufacturing facility in Maryland has joined Kite’s existing manufacturing facilities to form the largest, dedicated in-house cell therapy manufacturing network in the world.
-
Kite, a Gilead Company
@KitePharma
Congratulations to our CEO Christi Shaw on her recognition as one of the most influential CEOs in biopharma by @FiercePharma. We are thankful for her leadership in bringing cell therapy to more patients living with cancer.
FiercePharma
@FiercePharma
For the next few weeks, we'll be announcing our top 20 most influential people in biopharma. Today, we published our report on the top 5 CEOs: www.fiercepharma.com/pharma/most-influential-people-bioph…
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
At Gilead, 2021 was the year we moved ‘Forward and Onward Together.’ Through the promotion of inclusion and diversity, transformative science and renewed commitments to sustainability, we worked toward furthering our mission of making the world a healthier place for everyone.
-
Kite, a Gilead Company
@KitePharma
We're honored to be this year’s recipient of the Sustainability Quality Award Grand Prize from @santamonicabiz, @sustainablework & @santamonicacity, a recognition of businesses in the Santa Monica, California, region putting sustainable practices into action.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We’re proud to be named one of America's Best Employers for Diversity by @Forbes. Building a diverse workforce is critical to our mission of creating a better, healthier world – and we’ll continue to provide a supportive, innovative place for employees.
-
Kite, a Gilead Company
@KitePharma
At Kite, we are committed to minimizing our environmental footprint through an ambitious goal of reducing our energy, water, and waste footprint to zero. #earthday
-
Kite, a Gilead Company
@KitePharma
As our global manufacturing network grows to meet the needs of patients now and in the future, we’re proud to announce the @US_FDA has approved commercial production at our new #cartcell therapy manufacturing facility in Frederick, Maryland.
-
Kite, a Gilead Company
@KitePharma
Large B-cell lymphoma (LBCL) is the most common type of non-Hodgkin lymphoma. Between 30% to 40% of patients with #lbcl will need second-line treatment as their cancer will likely relapse or become refractory to treatment.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We’re featuring Julie, a wife and mother of two from Pennsylvania who was diagnosed with large B-cell lymphoma. Here, she shares her #cartcell therapy journey.
-
Kite, a Gilead Company
@KitePharma
Kite’s singular focus is advancing cell therapy to treat and potentially cure cancer. Our industry-leading technology is changing the way cancer is treated by engineering a patient’s white blood cells to target and attack their cancer cells.
-
Kite, a Gilead Company
@KitePharma
CAR T-cell therapy is changing the future of cancer treatment. Kite is proud to have more than 110 authorized treatment centers in the U.S. where patients can receive CAR T.
-
Kite, a Gilead Company
@KitePharma
Cell therapy is a team sport. Thank you to all clinical trial participants, caregivers, researchers & physicians who helped pave the way for the @US_FDA approval of our #cartcell therapy as an initial treatment option for patients with relapsed/refractory large B-cell #lymphoma.
-
Kite, a Gilead Company
@KitePharma
We are pleased to announce that @US_FDA has approved our #cartcell therapy as an initial treatment for patients with relapsed/refractory large B-cell lymphoma – the first treatment to provide a new option for patients vs. standard of care in nearly 30 years.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We’re proud to have three employees honored by the HBA. Congratulations to Luminary Keeley Wettan & Rising Stars Jill Gannon and @KitePharma’s Sophia Sharp-Donaldson, who were recognized for their work here and for helping advance the impact and influence of women in healthcare.
Healthcare Businesswomen’s Association (HBA)
@HBAnet
Congrats! Michelene Taptich, @EndoIntlplc; Amy Hutnik, Paula Hackl, @EVERSANAcompany; Doreen Eckert, @evoke_group; Susan Garfield, @EYnews; Keeley Wettan, Jill Gannon, Sophia Sharp-Donaldson @GileadSciences
hbanet.org/2022-rising-stars-and-luminaries
#hbawoty22 #hbaimpact #genderequality #healthcare -
Kite, a Gilead Company
@KitePharma
As we strive to extend the lives of people with hard-to-treat blood cancers, we thank those who shared their #celltherapy knowledge and experience at this year’s #ebmt2022.
-
Kite, a Gilead Company
@KitePharma
Large B-cell #lymphoma is an aggressive (fast-growing) blood cancer, accounting for every 1 out of 3 lymphomas in the United States.
-
Kite, a Gilead Company
@KitePharma
We’re honored that our study evaluating #cartcell therapy as part of first-line treatment in patients with high-risk large B-cell lymphoma was featured in @NatureMedicine. Congratulations to all the scientists involved!
-
Kite, a Gilead Company
@KitePharma
People with aggressive #bloodcancers have limited treatment options. We are working to change this.
Join us at #ebmt2022, where we will present our latest transformational #celltherapy research. -
Kite, a Gilead Company reposted
Reuters Events Pharma
@RE_Pharma
Fantastic to hear Christi Shaw explaining how @KitePharma are changing the treatment paradigm in blood cancer. #repharmausa
-
Kite, a Gilead Company
@KitePharma
Our singular focus is cell therapy to treat and potentially cure #cancer. As the #celltherapy leader, Kite has more approved CAR T indications to help more patients than any other company.
-
Kite, a Gilead Company
@KitePharma
Working at Kite is more than a job. Every day, we get the opportunity to develop potentially life-saving therapies for the patients who need them most.
-
Kite, a Gilead Company
@KitePharma
This #internationalwomensday and every day, we stand with women worldwide to #breakthebias of gender inequality as we celebrate the remarkable achievements of women making a difference in the STEM field. #iwd2022
-
Kite, a Gilead Company
@KitePharma
Today, we recognize the dedication and commitment of our employees who are instrumental in advancing cell therapy as a transformative treatment option for people living with cancer. #employeeappreciationday
-
Kite, a Gilead Company
@KitePharma
Happening now on our Facebook page: We’re teaming up with the @Cure_FL this #rarediseaseday for our discussion, “Living with Follicular Lymphoma.”
-
Kite, a Gilead Company
@KitePharma
On this #nationalcaregiversday, we celebrate the often-untold stories of caregivers like Ricky, Scott and Crystal along with millions of other people providing unconditional support to their loved ones navigating cancer care.
This media couldn't be displayed. See it on the original post. -
Kite, a Gilead Company
@KitePharma
Head to our Facebook page on #rarediseaseday (2/28) for a discussion with @Cure_FL on living with follicular #lymphoma. We’ll discuss support for patients and caregivers, the importance of self-advocacy and why developing a treatment strategy is critical.
-
Kite, a Gilead Company
@KitePharma
#celltherapy is a one-time treatment that is changing the way #cancer is treated. Our technology uses the power of a patient’s own immune system to attack certain types of cancer cells. Learn more about how it works.
-
Kite, a Gilead Company
@KitePharma
At Kite, our #celltherapy research is seeking to change the outlook for patients with many different types of #bloodcancer. #cart22
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Today we’re celebrating the historic accomplishments of #womeninscience and cheering on the #girlsinstem who will carry on their legacy. On this International Day of Women and Girls in Science, we look forward to their contributions and remain committed to gender equity in STEM.
-
Kite, a Gilead Company
@KitePharma
Our cell therapy specialists manufacture individualized therapies for people living with certain cancers who have failed other treatments. It’s this personal connection to the patients that we serve that makes working at Kite so unique.
-
Kite, a Gilead Company
@KitePharma
We are excited to join @EHA_Hematology and @TheEBMT at the 4th European CAR T-cell Meeting to share our latest advances in #celltherapy. We’re committed to bringing #cart to more people with #bloodcancer. #cart22
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
At Gilead, we’re survivors and supporters, storytellers and scientists – and we all have a tireless drive to help change the course of cancer. Today, we’re sharing what #worldcancerday #meanstome, and we’re here to learn.
-
Kite, a Gilead Company
@KitePharma
We are committed to bringing the hope of survival to more patients through #cartcell therapy. On #worldcancerday, we honor everyone working toward a world with cures for cancer.
-
Kite, a Gilead Company
@KitePharma
We are driven by our mission to deliver potentially life-saving cancer therapies to patients who have exhausted other options. Join us in celebrating the strength and resilience of the cancer community ahead of #worldcancerday.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Jonathan Tsang is a process scientist dedicated to the continuous improvement of @KitePharma’s CAR T-cell therapy manufacturing processes. Learn about what makes his work so critical. #creatingpossible gilead.inc/3IZFx8f
-
Kite, a Gilead Company
@KitePharma
#news: The @US_FDA has approved a new label update for our #cartcell therapy that may help physicians manage certain treatment side effects.
-
Kite, a Gilead Company
@KitePharma
We're proud to be part of @GileadSciences, recently recognized as a Best Place to Work for LGTBQ+ Equality by the @HRC Foundation.
Gilead Sciences
@GileadSciences
We’re pleased to be named a Best Place to Work for LGTBQ+ Equality by the @HRC Foundation. We’ve achieved a 100% rating in the Corporate Equality Index for five consecutive years, and we celebrate our diverse workforce and inclusive culture. #cei2022
-
Kite, a Gilead Company
@KitePharma
Non-Hodgkin lymphoma is one of the most common cancers in the United States. Through cell therapy, a one-time treatment, we’re providing hope for patients living with difficult-to-treat cancers like NHL. #lymsm
-
Kite, a Gilead Company
@KitePharma
Our team is driven to fundamentally change the way people think about cancer treatment. Learn how we are advancing #celltherapy for patients who have exhausted other options.
-
Kite, a Gilead Company
@KitePharma
Using our industry-leading #celltherapy technology, we engineer a person’s own T cells to recognize and attack certain types of cancer cells. See how we’re harnessing the power of the immune system to fight cancer.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
On Dr. Martin Luther King Jr. Day, we continue to be inspired by the indelible mark he left on the world. At Gilead, we aim to further Dr. King’s legacy through our efforts to promote equity, inclusion and diversity here and in partnership with communities we serve. #mlkday2022
-
Kite, a Gilead Company
@KitePharma
As the leader in #celltherapy, we are fundamentally changing the way people think about cancer when initial treatment options fail. Learn more about our technology.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Sherrie Musick manages the materials needed to manufacture @KitePharma's cell therapies and helps ship engineered cells to authorized cancer treatment centers across the United States. Find out what inspired her to join the company. gilead.inc/3K16VEq #creatingpossible
-
Kite, a Gilead Company
@KitePharma
By expanding the use of #celltherapy to multiple cancer types, additional geographies and earlier lines of therapy – and getting #cart to patients faster – we can potentially reach more patients facing difficult-to-treat cancers.
-
Kite, a Gilead Company
@KitePharma
As we head into the new year, our focus on the cure remains unchanged. We are committed to bringing #cartcell therapy to patients who have exhausted other options against cancer. Learn about our mission.
-
Kite, a Gilead Company
@KitePharma
This holiday season, we share our appreciation for those who support our mission to advance CAR T-cell therapy for patients who may benefit. Happy holidays from all of us at Kite!
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced primary results from our phase 2 study evaluating #cartcell therapy as part of first-line treatment in patients with high-risk large B-cell lymphoma. #ash21
-
Kite, a Gilead Company
@KitePharma
Day 3 of #ash21 is here! Join us for poster and oral presentations highlighting the latest advances in our #celltherapy portfolio.
-
Kite, a Gilead Company
@KitePharma
After her non-Hodgkin lymphoma didn’t respond to chemotherapy or a stem cell transplant, Emily thought she had run out of options. Then she enrolled in a #cart clinical trial. See her story. #ash21
-
Kite, a Gilead Company
@KitePharma
Did you guess D (all the above) in our previous poll question about large B-cell lymphoma? #lbcl is one of the most common blood cancers found in men between the ages of 65-74 years old.
-
Kite, a Gilead Company
@KitePharma
We are excited to share results from our phase 3 trial of #cartcell therapy in second-line relapsed/refractory large B-cell lymphoma today at #ash21. Tune in to our plenary session to learn more.
-
Kite, a Gilead Company
@KitePharma
It's Day 2 of #ash21. What's on your schedule? We're sharing presentations highlighting the latest advances in approved and investigational CAR T-cell therapies for lymphoma. #lymsm
-
Kite, a Gilead Company
@KitePharma
As a physician, Celeste felt extremely discouraged after she had exhausted multiple treatment options in her battle against large B-cell #lymphoma. Then she enrolled in a #cart clinical trial. Watch her story. #ash21
-
Kite, a Gilead Company
@KitePharma
Sharing new results from our phase 2 study for adult patients with relapsed or refractory indolent non-Hodgkin #lymphoma. #ash21
-
Kite, a Gilead Company
@KitePharma
We are pleased to share five-year follow up data from our pivotal study of #cartcell therapy in adult patients with refractory large B-cell lymphoma. #ash21
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced results from our landmark phase 3 study of #cartcell therapy versus standard of care in second-line relapsed or refractory large B-cell lymphoma. #ash21
-
Kite, a Gilead Company
@KitePharma
We’re excited for Day 1 of #ash21. Join us to learn about our latest advances in #cartcell therapy. #lymsm
-
Kite, a Gilead Company
@KitePharma
Which of the following statements is true about large B-cell lymphoma? #ash21
-
Kite, a Gilead Company
@KitePharma
We’re excited to share our latest innovations in #cartcell therapy at #ash21.
-
Kite, a Gilead Company
@KitePharma
With our industry-leading pipeline and latest research, we're committed to bringing #cartcell therapy to as many eligible patients as possible. Learn more about our progress.
-
Kite, a Gilead Company
@KitePharma
Our engineered T-cell therapies attack and destroy #cancer tumors. Our work in #cart treatment is transforming cancer care for the people who need it most.
-
Kite, a Gilead Company
@KitePharma
At Kite, our mission of advancing our potentially life-saving CAR T-cell therapies is driven by the patients we treat. See Shon’s story. www.gilead.com/stories
-
Kite, a Gilead Company
@KitePharma
Our mission is to provide transformational cancer treatment through #celltherapy, a customized treatment that genetically modifies immune cells to target tumors.
-
Kite, a Gilead Company
@KitePharma
With #cartcell therapy, we're developing personalized treatments to provide people living with different types of blood cancer more options and hope for the future.
-
Kite, a Gilead Company
@KitePharma
Cancer doesn’t just impact the patient — it affects everyone who loves them. This month, we recognize caregivers and their unwavering support for family members navigating cancer care with #cartcell therapy. #familycaregiversmonth
-
Kite, a Gilead Company
@KitePharma
Kite is honored to be this year’s recipient of the #pantheon2021 Strategic Partnership of the Year Award, a recognition of our collaboration with Shoreline Biosciences, Inc. The annual Pantheon Awards is hosted by @CALifeSciences. www.califesciences.org/pantheon/
-
Kite, a Gilead Company
@KitePharma
We're presenting data from more than 20 abstracts with @GileadSciences at this year’s @ASH_hematology annual meeting to highlight our latest innovations in cell therapy. #ash21
-
Kite, a Gilead Company
@KitePharma
Through years of focused efforts and important industry and academic partnerships, we remain committed to making progress in curing #cancer.
-
Kite, a Gilead Company
@KitePharma
Acute Lymphoblastic Leukemia is a fast-growing and aggressive blood cancer and can progress quickly if left untreated. That’s why we’re committed to advancing #cartcell therapy to change the way we treat #all.
-
Kite, a Gilead Company
@KitePharma
After a decade of treatment for Branden’s acute lymphoblastic leukemia (#all), his doctor suggested #cartcell therapy, an option that brought hope. “I was just lucky to live long enough to see this advance come out of the labs and into my life.” Watch Branden’s story.
-
Kite, a Gilead Company
@KitePharma
More information about a new treatment just approved for adult patients living with acute lymphoblastic leukemia can be found through our authorized #cartcell therapy treatment centers spanning the U.S.
-
Kite, a Gilead Company
@KitePharma
#news: Today, the @US_FDA granted approval for the first and only #cartcell therapy for adult patients (18+) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. #all
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced our submission of a supplemental Biologics License Application (sBLA) to the @US_FDA for a #cartcell therapy for adult patients with relapsed or refractory large B-cell lymphoma as a second-line treatment option.
-
Kite, a Gilead Company
@KitePharma
Our Kite and @GileadSciences #lightthenight team is honored to walk in memory of those we lost to #bloodcancer as well as the survivors, caregivers and people who are currently living with the disease.
-
Kite, a Gilead Company
@KitePharma
In honor of Blood Cancer Awareness Month, we’re proud to shed light on organizations like @Cure_FL in their fight against blood cancers. #bcam
-
Kite, a Gilead Company
@KitePharma
Our mission to transform the way we treat cancer depends on our passionate researchers who are devoted to progressing the field of #celltherapy. #worldcancerresearchday
-
Kite, a Gilead Company
@KitePharma
In recognition of #worldlymphomaawarenessday, we join the global mission to bring hope to patients, like Chuck, through the potential of #cartcell therapy. Read his story.
-
Kite, a Gilead Company
@KitePharma
On #worldleukemiaday, we proudly join the global movement to raise awareness of this blood cancer and recognize the strength and resilience of those impacted by #leukemia. #wld21
-
Kite, a Gilead Company
@KitePharma
In honor of #bloodcancerawarenessmonth, we stand with those affected by this disease. We will continue to fight for advancing #celltherapy treatment options that have the potential to save lives. #bcam
-
Kite, a Gilead Company
@KitePharma
Large B-cell #lymphoma is a type of non-Hodgkin lymphoma (NHL). Approximately 50% of patients with LBCL will experience a relapse or become refractory after first-line treatment.
-
Kite, a Gilead Company
@KitePharma
Our team members, like Behzad Kharabi, are committed to developing next-generation technologies that could change how we treat adult acute lymphoblastic #leukemia (ALL).
-
Kite, a Gilead Company
@KitePharma
Expanding innovative cancer therapies for more #lymphoma and #leukemia patients is not only a top priority – it’s our mission.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we’ve announced the @US_FDA clearance of an Investigational New Drug (IND) for a new research opportunity in #cartcell therapy that targets two antigens highly expressed in large B-cell lymphomas – CD19 and CD20.
-
Kite, a Gilead Company
@KitePharma
We harness the power of a patient's own immune system by isolating and activating a patient's T cells before engineering them to fight certain types of #cancer.
-
Kite, a Gilead Company
@KitePharma
We remain focused on our mission to cure cancer. By transforming the way we think about treating fast-growing and aggressive blood cancers like acute lymphoblastic #leukemia, we aim to provide more treatment options to patients who need it most.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced a collaboration with Appia Bio to research and develop allogenic cell therapies for cancer.
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced that a #cartcell therapy is now publicly funded and available in Australia for certain adult patients with four types of non-Hodgkin lymphoma who meet the eligibility criteria.
-
Kite, a Gilead Company
@KitePharma
Our industry-leading #celltherapy technology uses the power of a person's own immune system to fight cancer.
-
Kite, a Gilead Company
@KitePharma
It's no longer science fiction – it's just science. We're continuing our efforts to broaden the use of #celltherapy to target and treat B-cell malignancies.
-
Kite, a Gilead Company
@KitePharma
Our mission is ambitious: cure cancer. Cell therapy has already changed the way cancer is treated. Now we're focused on developing #celltherapies to help a broader range of patients with difficult-to-treat cancers.
-
Kite, a Gilead Company
@KitePharma
We are excited to welcome Bob Shelley to Kite as Vice President of Global Market Access and Pricing.
-
Kite, a Gilead Company
@KitePharma
We bring industry-leading #celltherapy technology to patients who need it most. By redirecting genetically modified T cells, our therapies use the body’s own immune system to recognize and attack certain types of cancer cells.
-
Kite, a Gilead Company
@KitePharma
Christi Shaw joined @PharmaVOICE’s Taren Grom, sharing her personal story of loss and how it led her on a mission to change the way #cancer is treated by educating more people on Kite’s industry-leading cell therapy technology as a next generation treatment.
-
Kite, a Gilead Company
@KitePharma
Our Global Head of Technical Operations Chuck Calderaro joins @mattpillar, host of the #businessofbiotech podcast, to discuss Kite’s capabilities and goals of scaling #celltherapy.
-
Kite, a Gilead Company
@KitePharma
Wishing everyone in the U.S. a safe and happy Independence Day! #july4th
-
Kite, a Gilead Company
@KitePharma
Long-term remission for adults living with relapsed/refractory acute lymphoblastic #leukemia (ALL) is often a challenge. We’re committed to pursuing #cartcell therapy as a transformative treatment option for patients.
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced top-line results from our landmark study investigating the use of #cartcell therapy compared to standard of care in second-line relapsed/refractory large B-cell lymphoma.
-
Kite, a Gilead Company
@KitePharma
#news: Our application for a #cartcell therapy for adult patients (18+) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in Europe has been validated and is now under review by the European Medicines Agency.
-
Kite, a Gilead Company
@KitePharma
#news: We are pleased to announce the first CAR T-cell therapy in China has received approval by the China National Medical Products Administration (NMPA).
-
Kite, a Gilead Company
@KitePharma
#cartcell therapy is changing the way hematologic malignancies are treated. At Kite, we’re focused on bringing this transformative, one-time treatment to as many appropriate patients as possible who may benefit.
-
Kite, a Gilead Company
@KitePharma
Wishing a Happy #fathersday to dads everywhere.
-
Kite, a Gilead Company
@KitePharma
#news: Today, we announced a strategic partnership with Shoreline Biosciences to develop novel allogeneic cell therapies across a variety of #cancer targets.
-
Kite, a Gilead Company
@KitePharma
#news: Today we announced long-term data from a real-world analysis in patients with relapsed or refractory indolent follicular #lymphoma at #eha2021.
-
Kite, a Gilead Company
@KitePharma
Advancing #cart therapies for patients across lymphomas – including relapsed/refractory follicular lymphoma – is a cornerstone of our research.
-
Kite, a Gilead Company
@KitePharma
When chemotherapy wasn’t bringing Shon the results he was looking for, his doctor suggested an option that brought hope. #cart #celltherapy
-
Kite, a Gilead Company
@KitePharma
As we work to bring the hope of survival to people with aggressive #bloodcancers, we’d like to thank those attending and sharing their knowledge at #eha2021.
-
Kite, a Gilead Company
@KitePharma
We strive to improve and extend the lives of people with aggressive #bloodcancers. As such, we are honoured to join @EHA_Hematology and share our transformational #celltherapy research at #eha2021.
-
Kite, a Gilead Company
@KitePharma
Join us in celebrating life and honoring #cancer survivors everywhere today. Who are you celebrating? #nationalcancersurvivorsday #ncsd2021
-
Kite, a Gilead Company
@KitePharma
Today we celebrate all those who have survived #cancer and the loved ones that stood with them.
Kite colleagues share some of the people who inspire their focus on the cure in honor of #nationalcancersurvivorsday. #ncsd2021 -
Kite, a Gilead Company
@KitePharma
#news: We’ve announced results from our Phase 2 study for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic #leukemia (ALL) at #asco21 @GileadSciences
-
Kite, a Gilead Company
@KitePharma
Join us today from your home office as we present results from the preliminary analysis of our Phase 2 study for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic #leukemia (ALL) at #asco21.
-
Kite, a Gilead Company
@KitePharma
“In the field of oncology, I truly believe the best is ahead – there is so much more innovation for us to look forward to.”
Kite CEO Christi Shaw shares her thoughts on progress for patients ahead of #asco21 and #eha2021. -
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
As the oncology community gets ready for #asco21, read the perspectives of @KitePharma clinical researcher Behzad Kharabi, and @MoffittNews clinician Bijal Shah, who discuss the need for finding new therapies in adult acute lymphoblastic #leukemia: www.gilead.com/stories
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Today, as #pridemonth begins, we celebrate the diverse identities of members of LGTBQ+ communities around the world. We’re committed to helping our employees, patients and partners be their authentic selves and to fostering an environment that promotes equity for all.
-
Kite, a Gilead Company
@KitePharma
The future of #celltherapy is closely tied to innovation in manufacturing. Automation will enable us to efficiently grow our operations so we can help more patients. #uclalabest2021
-
Kite, a Gilead Company
@KitePharma
Members of our Kite Leadership Team will share how Los Angeles is playing a role in Kite’s effort to lead #cartcell therapy innovation around the world at #uclalabest2021 tomorrow at 2pm PT. Register to join here: www.eventbrite.com/e/ucla-labest-2021-the-premier-bioscie…
-
Kite, a Gilead Company
@KitePharma
We're proud to join the Los Angeles life sciences community at the LA Bioscience Ecosystem Summit 2021 (LABEST) this week. Looking forward to discussing how to scale #celltherapies to reach more patients globally. #uclalabest2021
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw joined fellow industry leaders at this year’s World Medical Innovation Forum, exploring ways #celltherapy will change the healthcare landscape and highlighting our commitment to reducing barriers for patients in accessing treatment. #wmif21
-
Kite, a Gilead Company
@KitePharma
We’re proud to virtually attend #asco21 alongside @GileadSciences to share our latest advances in #cartcell therapy. www.gilead.com/news/news-details/2021/gilead-kite-oncolog…
Gilead Sciences
@GileadSciences
This #asco21, we’re showcasing the collective efforts of the Gilead and @KitePharma teams to help address the unmet medical needs of people living with cancer. Here’s what we’ve been working on: www.gilead.com/news/news-details/2021/gilead-kite-oncolog…
-
Kite, a Gilead Company
@KitePharma
We believe in fighting cancer, even after first and second line treatments fail – learn more about #celltherapy, a personalized treatment that genetically modifies immune cells to target tumors.
-
Kite, a Gilead Company
@KitePharma
Acute lymphoblastic leukemia, also called acute lymphocytic leukemia (or ALL), starts in the bone marrow and can progress quickly if left untreated, which is why we’re studying the impact of #celltherapy in ALL.
-
Kite, a Gilead Company
@KitePharma
Our industry-leading pipeline of cell therapies brings hope to patients and their families after initial lines of #cancer treatment fail. During this National Cancer Research Month and every month, we are committed to advancing our focus on the cure. #ncrm21
-
Kite, a Gilead Company
@KitePharma
Without their support and care, we wouldn’t be where we are today. Thank you to moms everywhere. #mothersday
-
Kite, a Gilead Company
@KitePharma
We are excited to welcome Adriana Herrera to Kite as Vice President of U.S. Commercial.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Last year was a year like no other. At Gilead, we rose to the challenge and responded to the pandemic while continuing to help advance medicines for life-threatening diseases, contribute to positive social change and grow our business sustainably: www.gilead.com/news-and-press/annual-report/year-in-revie…
-
Kite, a Gilead Company
@KitePharma
Today, we are thrilled to welcome Mary Lynn Carver as Global Head of Public Affairs at Kite.
-
Kite, a Gilead Company
@KitePharma
We’re working to harness the power of a patient’s own immune system to treat both hematological and solid tumors.
-
Kite, a Gilead Company
@KitePharma
When we look back at the progress of #cartcell therapy, we’re proud to play a pivotal role in advancing treatment options for people fighting #cancer.
-
Kite, a Gilead Company
@KitePharma
How #cartcell therapy works:
1. Collect patient's white blood cells
2. Isolate and activate T-cells
3. Engineer T-cells with CAR gene
4. Grow and expand number of T-cells
5. Infuse same patient with engineered T-cells -
Kite, a Gilead Company
@KitePharma
At Kite, part of our commitment to patients is considering the impact we have on our planet. #earthday
-
Kite, a Gilead Company
@KitePharma
At Kite, we’re working to expand the potential of #cart cell therapy in the fight against cancers like large B-cell #lymphoma, which accounts for 1 out of every 3 lymphomas.
-
Kite, a Gilead Company
@KitePharma
Getting #celltherapy – a one-time treatment with curative potential – to more patients is a top priority for everyone in the industry. From advancing the therapy to breaking down barriers, Kite CEO Christi Shaw shares what motivates her every day.
-
Kite, a Gilead Company
@KitePharma
Thank you for a great conversation @HBAPacific!
HBA Pacific Region
@HBAPacific
Don’t miss the chance to hear from cell therapy industry leaders! Tue April 13 at 5-6:30pm PST. Register: my.hbanet.org/EVENTS-PROGRAMS/AddEdit/EventDetails/Meetin…
Thank you to our sponsors! - @AllogeneTx @Atarabio @Deloitte @KitePharma Klein Hersh International Westwood & Wilshire LLC @Karma Biotechnologies -
Kite, a Gilead Company
@KitePharma
What does the #cartcell therapy process look like? CAR T-cell therapy is a complex process that requires speed, efficiency and a highly trained #celltherapy specialist.
-
Kite, a Gilead Company
@KitePharma
During #nationalcancercontrolmonth, we recognize the importance of improving #cancer treatments. While not all cancers can be controlled, we are committed to creating new paths for patients through innovative therapy options.
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced our submission of a supplemental Biologics License Application (sBLA) to the @US_FDA for a #cartcell therapy for adult patients (18+) with relapsed or refractory B-cell precursor acute lymphoblastic #leukemia, an aggressive type of blood cancer.
-
Kite, a Gilead Company
@KitePharma
We’re proud to manufacture the first #cartcell therapy to demonstrate four-year follow-up data in third-line large B-cell lymphoma, a difficult-to-treat disease that affects many every year.
-
Kite, a Gilead Company
@KitePharma
When other treatments fail, we aim to give people living with #cancer a transformative treatment option that will make a meaningful difference in their lives. #cart
-
Kite, a Gilead Company reposted
Biotechnology Innovation Organization
@IAmBiotech
Today we are celebrating #womenshistorymonth with @KitePharma CEO Christi Shaw. Hear what piece of advice she would give to her younger self ⬇️
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We stand in solidarity with our Asian-American and Pacific Islander employees. The recent attacks in Atlanta and the Bay Area are deplorable, and we condemn racism of any kind. Read more from Chairman and CEO Daniel O’Day: www.gilead.com/stories
-
Kite, a Gilead Company
@KitePharma
Proud to see our UK team win the #hsj Partnership of the Year award at the #hsjawards. This award recognises both Kite’s and Gilead’s commitment to delivering medicines for life-threatening illnesses & improving access to care by eliminating barriers through working partnerships.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
As COVID-19 began spreading across Europe last March, supply chains were severely disrupted. See how the dedicated @KitePharma logistics team worked to transport live cells and help people with cancer: www.gilead.com/stories #creatingpossible
-
Kite, a Gilead Company
@KitePharma
Thank you @TheEBMT for another successful virtual meeting. We will continue working towards advancing research in #celltherapy to better understand difficult-to-treat hematologic malignancies to support unmet patient needs. #ebmt21
-
Kite, a Gilead Company
@KitePharma
At Kite, improving the lives of people living with cancer is our number one goal. Finding a cure is at the heart of everything we do.
-
Kite, a Gilead Company
@KitePharma
Together with @GileadSciences, we’re looking forward to joining @TheEBMT at this year’s #ebmt21 virtual meeting to share the latest advances in #celltherapy for difficult-to-treat blood cancers.
-
Kite, a Gilead Company
@KitePharma
At Kite, we're united by our mission to create a world with cures for #cancer.
-
Kite, a Gilead Company
@KitePharma
We #choosetochallenge gender inequality and celebrate the success and achievements of women this #internationalwomensday and every day. #iwd2021
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Read more about Chuck, who received #cartcell therapy to treat a form of non-Hodgkin lymphoma and now helps other patients with cancer: www.gilead.com/stories
-
Kite, a Gilead Company
@KitePharma
#news: We are pleased to announce the @US_FDA has granted accelerated approval to our #cartcell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
-
Kite, a Gilead Company
@KitePharma
Thank you to our entire Kite team for their relentless determination and commitment to delivering therapies to people living with blood cancer. #employeeappreciationday
-
Kite, a Gilead Company
@KitePharma
We’re pleased to share that data from two of our clinical trials in relapsed/refractory indolent non-Hodgkin lymphoma and high-risk large B-cell lymphoma have been selected for the @ASH_hematology 2021 Highlights of ASH virtual presentation. #lymphoma #cancerresearch
-
Kite, a Gilead Company
@KitePharma
We're committed to advancing #cartcell therapies for people living with rare #bloodcancers. Join us by listening, learning and educating others this #rarediseaseday.
-
Kite, a Gilead Company
@KitePharma
We're focused on helping more people with #cancer get the treatment they need by continuing to advance our industry-leading pipeline of #cart cell therapies.
-
Kite, a Gilead Company
@KitePharma
CARs, or chimeric antigen receptors, are composed of two distinct components. The first component can recognize a target, and the second can provide signals that lead an attack against #cancer cells.
-
Kite, a Gilead Company
@KitePharma
Today is #nationalcaregiversday, a chance to honor caregivers everywhere who sacrifice and give so much. Our CEO Christi Shaw shares her experience caring for her sister and advice on how society can better support caregivers.
-
Kite, a Gilead Company
@KitePharma
From an idea to initial discovery and now reality, #cart is a transformative treatment option for some people battling #bloodcancer when other treatments have failed. Learn more about our mission.
-
Kite, a Gilead Company
@KitePharma
We're proud to accept the Transplantation and Cellular Therapy Meetings 2021 (#tctm21) "Best Abstract" award for our Phase 2 study in patients with high-risk large B-cell #lymphoma.
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced new findings from our recent analysis of patients living with relapsed or refractory large B-cell #lymphoma that may advance care at #tctm21.
-
Kite, a Gilead Company
@KitePharma
#news: Today we announced @US_FDA clearance of an IND for our first CAR T-cell therapy targeted at C-type lectin-like molecule-1 (CLL-1) for relapsed/refractory acute myeloid leukemia (AML).
-
Kite, a Gilead Company
@KitePharma
We are excited to welcome Frank Neumann, MD, PhD, to Kite as our Global Head of Clinical Development.
-
Kite, a Gilead Company
@KitePharma
Globally, #lymphoma is one of the most common blood cancers in adults.
Our continued data advances are changing the way blood #cancer is treated. #cart21 -
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
On #worldcancerday, Merdad Parsey, our Chief Medical Officer, shares what’s happening in oncology at Gilead and @KitePharma: www.gilead.com/stories
-
Kite, a Gilead Company
@KitePharma
Matt’s #bloodcancer diagnosis in 2014 inspired him to reevaluate what was truly important in life, and ultimately led to a passion for helping others. He’s dedicated his career to advancing #cancer immunotherapies as a way to support people impacted by cancer. #worldcancerday
-
Kite, a Gilead Company
@KitePharma
As we remain focused on the cure, we’re continuously moved and motivated by the stories of individuals and families impacted by cancer. We stand and fight with you, on #worldcancerday and every day. #iamandwill
-
Kite, a Gilead Company
@KitePharma
#news: We’re proud to support the 3rd European CAR T-cell Meeting alongside @EHA_Hematology and @TheEBMT to help address some of the hardest-to-treat forms of #cancer. #cart21
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Gilead celebrates the historical achievements and contributions of Black leaders. On this and every day, we aim to advance Black leadership and mitigate health disparities - and we stand with those working to promote racial equity and social justice. #blackhistorymonth
-
Kite, a Gilead Company
@KitePharma
We’re committed to making CAR T a reality for patients earlier in the treatment journey. Learn more about our industry-leading pipeline and our latest research.
-
Kite, a Gilead Company
@KitePharma
Biopharma leaders, including Kite CEO Christi Shaw, share insights from 2020 and predictions for what 2021 holds for the industry @PharmaScrip
-
Kite, a Gilead Company
@KitePharma
After undergoing two lines of chemotherapy to treat his diffuse large B-cell #lymphoma, Shon looked for other options. With #cartcell therapy, his own T cells attacked the cancer cells in his body.
-
Kite, a Gilead Company
@KitePharma
Our industry-leading #celltherapy technology uses the power of a person's own immune system to target & attack their tumors. It works by engineering a patient’s T cells to strengthen the body’s ability to kill certain types of #cancer cells. Learn more about our technology.
-
Kite, a Gilead Company
@KitePharma
We're proud to sponsor @FamilyReach’s Imagine Cancer Equity Series. Join the conversation about eliminating disparities in #cancer care on January 26 to learn more: familyreach.org/about-us/events/imagine
Family Reach
@familyreach
Join us on January 26 for a conversation about social determinants of health - focused on how collaboration across various industries can help eliminate disparities in #cancer care.
Register for free: us02web.zoom.us/webinar/register/WN_roWT-MxfR36jNlkAubottQ #sdoh
@Kate__Healy @cancerrights @LSimmsDC @ACSCAN -
Kite, a Gilead Company
@KitePharma
Our #celltherapy pipeline holds the power to transform the way cancer is treated. Learn more.
-
Kite, a Gilead Company
@KitePharma
We are so pleased to welcome Franco Marincola, MD, to Kite as Global Head of Cell Therapy Research.
-
Kite, a Gilead Company
@KitePharma
How are we changing the way #cancer is treated? By continuing to explore broadened applications of cell therapy to treat diseases like indolent non-Hodgkin lymphoma, a type of lymphoma that grows and spreads slowly. #lymsm
-
Kite, a Gilead Company
@KitePharma
Our goal is to help as many people living with #cancer as possible by developing cell therapies with curative intent. Learn more about our focus on the cure.
-
Kite, a Gilead Company
@KitePharma
#news: We’ve entered into a research collaboration with Oxford BioTherapeutics to evaluate five novel targets for a number of hematologic and solid tumor indications.
-
Kite, a Gilead Company
@KitePharma
In 2021, our team remains focused on our mission to advance #cartcell therapy for even more patients.
-
Kite, a Gilead Company
@KitePharma
We’re grateful for everyone who contributed to advancing our focus on the cure this year. Thank you and Happy Holidays from all of us at Kite!
-
Kite, a Gilead Company
@KitePharma
#news: @EU_Commission grants conditional marketing authorization for our second #cartcell therapy. @EMA_News
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
As #ash20 draws to a close, we’re more excited than ever about innovation in oncology – and we remain committed to working with @Kitepharma to help address some of the hardest-to-treat forms of cancer. Learn more about our work.
-
Kite, a Gilead Company
@KitePharma
A big #ashkudos to @ASH_hematology for another great year! Our team was honored to attend #ashfromhome to share our latest strides in #cartcell therapy research. We look forward to another year of innovating for patients.
ASH
@ASH_hematology
Thank you #hemetwitter for making #ash20 a blast! We hope to see you all in Atlanta next year.
(The meeting isn't over yet! Stick around for Poster Walks Dec. 9-11!) -
Kite, a Gilead Company
@KitePharma
Hold your calendars for our next #ash20 oral presentation where we will present data from a Phase 2 study of an investigational therapy for patients with relapsed/refractory indolent non-Hodgkin lymphoma. Head to our press release to learn more.
-
Kite, a Gilead Company
@KitePharma
We are excited to share results from our Phase 2 study of an investigational therapy in patients with high-risk large B-cell lymphoma (LBCL) today at #ash20. Tune in or read our announcement to learn more.
-
Kite, a Gilead Company
@KitePharma
At Kite, we strive to understand patients’ real-world experiences and challenges when living with hematological cancers. Event-free survival (EFS) as a unique primary endpoint offers us the opportunity to understand life after treatment. #ash20
-
Kite, a Gilead Company
@KitePharma
Our #ash20 day 2 agenda is now available! Join us to hear about the latest data in large B-cell lymphomas, non-Hodgkin #lymphoma and acute lymphoblastic leukemia.
-
Kite, a Gilead Company
@KitePharma
Our data at #ash20 build on our #cartcell therapy franchise and offer practice-changing potential in new indications. We’re proud to continue our work toward the goal of curing cancer.
-
Kite, a Gilead Company
@KitePharma
Advancing CAR T
Target and attack tumors
Focused on the cure
#ashaiku #ash20 -
Kite, a Gilead Company
@KitePharma
We’ve announced results from our Phase 2 study of an investigational therapy for patients with relapsed/refractory indolent non-Hodgkin lymphoma at #ash20.
-
Kite, a Gilead Company
@KitePharma
Coming up at #ash20: We will be sharing one-year follow up results for patients with relapsed/refractory mantle cell lymphoma (MCL). Tune in or read our announcement to learn more.
-
Kite, a Gilead Company
@KitePharma
#news: Our #cartcell therapy portfolio now includes four-year survival data in relapsed/refractory large B-cell lymphoma (LBCL). Follow along for our latest updates with @GileadSciences at #ash20.
-
Kite, a Gilead Company
@KitePharma
It’s day 1 of #ash20. What’s on your agenda? We’re excited for poster presentations demonstrating our most recent advances in lymphoma treatment. #lymsm
-
Kite, a Gilead Company
@KitePharma
Two colleagues from our @GileadSciences and Kite #immunooncology clinical research teams, Mark and Mauro, share their perspectives on unique and novel ways to attack #cancer cells, as well as the progress that’s been made for patients. #ash20
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We’re looking forward to participating in the #ashfromhome meeting and presenting our work alongside @KitePharma colleagues. #ash20
-
Kite, a Gilead Company
@KitePharma
As the first company with two FDA-approved #cart therapies, we’re proud to be a leader in engineered T cell therapy. Learn more about our progress at #ash20.
-
Kite, a Gilead Company reposted
STAT
@statnews
Even before the coronavirus, patients seeking CAR-T cancer treatments had to hope their therapy could make it through a byzantine, transatlantic relay race. Closed borders and cancelled flights made it nearly impossible. www.statnews.com/2020/11/30/how-are-we-going-to-get-on-th…
-
Kite, a Gilead Company reposted
Rick Berke
@rickberke
‘How are we going to get on that plane?’: The transatlantic race to deliver CAR-T cancer therapy during the pandemic.
Absorbing narrative about @KitePharma by @EricBoodman
www.statnews.com/2020/11/30/how-are-we-going-to-get-on-th… via @statnews -
Kite, a Gilead Company
@KitePharma
We’ll be presenting (from home!) our latest scientific advances in hematologic malignancies with @GileadSciences at the @ASH_hematology annual meeting #ash20 #ashfromhome
-
Kite, a Gilead Company
@KitePharma
We’re proud to be a leader in engineered T cell therapy with a global manufacturing network designed to support healthcare professionals and patients at a rapid speed.
-
Kite, a Gilead Company
@KitePharma
CAR T #celltherapy is a one-time treatment that uses the power of a person’s immune system to fight #cancer. Watch the Fantastic Voyage of CAR T Cells to learn more.
-
Kite, a Gilead Company
@KitePharma
Cell therapy is changing the way #cancer is treated. See how we’re focused on fulfilling our ambitious goal of finding a cure for patients in need.
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw joined @FTLiveHealth for a fireside chat to discuss the future of #celltherapy:
“Our hope is that we’ll see #cart expand into earlier lines of treatment and new indications so more patients can have access to this transformative treatment option.” #ftpharma -
Kite, a Gilead Company
@KitePharma
Consistently learning from patient and physician experiences helps us to provide meaningful resources and solutions in cell therapy.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Together with @KitePharma, we’re looking forward to presenting data from 16 abstracts including some of our latest scientific advances in hematologic malignancies at #ash20.
-
Kite, a Gilead Company
@KitePharma
We’re proud to announce that we’ll be presenting data highlighting our latest advances in #celltherapy at the @ASH_hematology annual meeting #ash20. @GileadSciences
-
Kite, a Gilead Company
@KitePharma
When someone you love is battling #cancer, you are battling cancer too. Thank you to the caregivers who provide unconditional love and support to those navigating cancer and #cartcell therapy. #familycaregiversmonth
-
Kite, a Gilead Company
@KitePharma
Thank you for all you do for people impacted by #bloodcancer and those who love them @LLSusa
Light The Night
@LightTheNight
Thank you for your support in bringing light to the darkness of cancer!
-
Kite, a Gilead Company
@KitePharma
We're proud to be a #lightthenight sponsor and walk with survivors, caregivers and the entire #bloodcancer community to drive out the darkness of cancer. @LightTheNight @LLSusa
-
Kite, a Gilead Company
@KitePharma
As a pioneer in #celltherapy for over 10 years, we continue to remain innovative, agile and ambitious – and focused on the cure.
-
Kite, a Gilead Company
@KitePharma
Throughout #inclusionweek and every day, we’re honored to embrace and celebrate the diverse voices that make up our culture and drive our mission of curing #cancer forward.
-
Kite, a Gilead Company
@KitePharma
#news: Today, the @EMA_News #chmp issued a positive opinion for our second #cartcell therapy.
-
Kite, a Gilead Company reposted
Biotechnology Innovation Organization
@IAmBiotech
Chuck Calderaro, SVP and Global Head of Technical Operations of @KitePharma discusses the ways cell therapy is advancing science and changing medicine: “We can bring this concept of personalized medicine to life.” #bifdigital
-
Kite, a Gilead Company
@KitePharma
Using the power of the immune system, #celltherapy technology can help strengthen the body’s ability to kill certain types of #cancer cells.
-
Kite, a Gilead Company
@KitePharma
As part of our core values, inclusion and diversity empower us to innovate and better serve patients. We proudly celebrate #nationalcomingoutday and the diversity within Kite that helps us advance cancer care.
-
Kite, a Gilead Company
@KitePharma
We proudly celebrate and support #hispanicheritagemonth. SoCal Gileados is one of our employee-led resource groups dedicated to building community and creating a culture that inspires innovation. Melissa Castro, our SoCal Gileados lead, shares what this month means to her.
-
Kite, a Gilead Company
@KitePharma
Congrats to all the riders who participated in #rideonlrf in their own communities this year! Even though we are physically apart, together, we can make a difference for people living with lymphoma and those who love them! @lymphoma
-
Kite, a Gilead Company
@KitePharma
We're proud to be a sponsor of #rideonlrf, an annual event that unites #lymphoma survivors and their families to help support and fund potentially life-saving @lymphoma research. This year, riders will hit the road in their own communities for a safe and socially distanced ride.
-
Kite, a Gilead Company
@KitePharma
#celltherapy manufacturing is radically different from traditional pharmaceutical manufacturing because every therapy is individualized. Cell therapy specialists engineer a person’s own T cells to fight the #cancer cells in their body.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
.@LLSusa is pivoting to keep people living with blood cancers connected to support and services. Read more about the Gilead and Kite partner’s efforts to evolve amid the COVID-19 pandemic.
-
Kite, a Gilead Company
@KitePharma
Donating blood can make a big impact in the lives of others, especially for those battling cancer. We’re grateful for employees like Michelle who support people impacted by #cancer inside and outside of work, during #bcam and beyond. #givemorelife #donateblood
-
Kite, a Gilead Company
@KitePharma
Our Kite and @GileadSciences #lightthenight team is excited to honor people living with #bloodcancer and those who love them, survivors and those we’ve lost to blood cancer this fall. Learn more about @LightTheNight.
-
Kite, a Gilead Company
@KitePharma
After learning that two lines of chemotherapy to treat his diffuse large B-cell #lymphoma had failed, Shon and his wife Lisa felt defeated. With #cartcell therapy, they learned they could use Shon’s T cells to fight the #cancer cells in his body. #bcam
-
Kite, a Gilead Company
@KitePharma
Proud to be a part of @GileadSciences, recognized as a 2020 Working Mother 100 Best Company. #wm100best
Gilead Sciences
@GileadSciences
In recognition of being named a 2020 @_WorkingMother_ 100 Best Company, read about the experience of Mia Campitelli, Director of Public Affairs, balancing work and home during the pandemic. #wm100best
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
This #worldlymphomaawarenessday, watch a video and read more about Shon, who received #cartcell therapy to treat his advanced blood cancer. www.gilead.com/stories #creatingpossible #wlad2020
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw reflects on #bloodcancerawarenessmonth and shares her gratitude for everyone working to eradicate blood cancer. #bcam #wlad2020
-
Kite, a Gilead Company
@KitePharma
Defeating #lymphoma will require a global collaboration. We are grateful to everyone involved in this fight and are proud to support @knowyournodes on World Lymphoma Awareness Day. #wlad2020
-
Kite, a Gilead Company
@KitePharma
We are proud to support the #lymphoma community as a #lightitred for Lymphoma partner with the @Lymphoma Research Foundation. Join in on September 15 to help raise awareness. #bcam #wlad2020
-
Kite, a Gilead Company
@KitePharma
“The patients are my biggest motivation. Our work is very specific to each patient – we are literally holding a person’s cells in our hands.”
Hear from Kite Cell Therapy Specialist Jan Pineda what it’s like being on the front lines of #cartcell therapy manufacturing. #bcam -
Kite, a Gilead Company
@KitePharma
This is true. #lymphoma is the most common #bloodcancer in adults.
Kite, a Gilead Company
@KitePharma
True or False: #lymphoma is the most common #bloodcancer in adults? #bcam
-
Kite, a Gilead Company
@KitePharma
True or False: #lymphoma is the most common #bloodcancer in adults? #bcam
-
Kite, a Gilead Company
@KitePharma
#news: Today, we submitted a supplemental biologics license application to @US_FDA for our #cartcell therapy in relapsed or refractory indolent non-Hodgkin lymphomas
-
Kite, a Gilead Company
@KitePharma
September 4th is #worldleukemiaday, and we are proud to join the global movement to raise awareness of this blood #cancer. RT to support the patients and caregivers impacted by #leukemia. #wld20
-
Kite, a Gilead Company
@KitePharma
Today, we announced a research collaboration with @HiFiBiO to discover novel targets and antibodies against acute myeloid leukemia for use in cell therapies
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
In recognition of #bloodcancerawarenessmonth, read what motivates Jan Pineda, Cell Therapy Specialist at @KitePharma, as she works on the front lines of the CAR T manufacturing process. #creatingpossible #fightbloodcancer #bcam
-
Kite, a Gilead Company
@KitePharma
We are committed to advancing #celltherapy research for people living with blood cancer around the world. #ebmt20virtual
-
Kite, a Gilead Company
@KitePharma
Today marks the start of #ebmt20virtual. We are pleased to be part of this meeting and excited to share our #celltherapy research.
-
Kite, a Gilead Company
@KitePharma
#dyk: CARs are modified proteins composed of two distinct functional components that recognize and attack #cancercells through targets present on the surface
-
Kite, a Gilead Company
@KitePharma
Our mission is to transform the way #cancer is treated with #celltherapy and to help transform the lives of patients who may have exhausted all other options
-
Kite, a Gilead Company
@KitePharma
#news: Today, we are pleased to welcome Warner Biddle to Kite as Senior Vice President and Global Head of Commercial
-
Kite, a Gilead Company
@KitePharma
Cell therapy is one of the biggest advancements in modern medicine since the invention of combination chemotherapy.
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw reflects on her first year, lessons learned and the advancements made to support people living with #cancer
-
Kite, a Gilead Company
@KitePharma
When Shon heard about #cart cell therapy from his oncologist, he was excited to learn that his own T cells could be engineered to help fight the #cancer cells in his body. Read his story.
-
Kite, a Gilead Company
@KitePharma
Cancer is personal to us. Our committed team operates with quality, speed, agility and most of all – passion to push the boundaries of what is possible with #celltherapy. Join our mission today.
-
Kite, a Gilead Company
@KitePharma
#cartcell therapy technology uses the body’s own immune system to fight #cancer.
CARs recognize targets present on the surface of #cancercells and activate T cells to attack those cancer cells. -
Kite, a Gilead Company
@KitePharma
Together, we can continue to drive progress for patients. We look forward to continuing our research in #celltherapy and partnering with advocates and the broader community.
-
Kite, a Gilead Company
@KitePharma
We are incredibly proud to announce the approval our second #cartcell therapy and look forward to continuing our research for patients.
-
Kite, a Gilead Company
@KitePharma
#breaking: Today, the @US_FDA granted accelerated approval of our second #cartcell therapy.
-
Kite, a Gilead Company
@KitePharma
#icymi: Our new European manufacturing facility brings #celltherapy production closer to patients in Europe and the surrounding regions, reducing the time it takes #cartcells to reach patients by almost a week.
-
Kite, a Gilead Company
@KitePharma
Our singular focus is #celltherapy, which we believe has the potential to change the way #cancer is treated
-
Kite, a Gilead Company
@KitePharma
“For me, keeping the patient front and center has always been my priority.”
Kite CEO Christi Shaw shared insights from her career journey with our 2020 Summer #intern Class to inspire the next generation of scientists and #healthcare leaders. -
Kite, a Gilead Company
@KitePharma
We’re honored to join @CancerSupportHQ's 2020 Virtual Celebration tonight. Thank you to the CSC team for the important work you do for people impacted by #cancer every day!
-
Kite, a Gilead Company
@KitePharma
#celltherapy harnesses the power of the immune system to fight #cancer. This one-time treatment uses a person’s own T cells to recognize and attack certain types of cancer cells. See how it works.
-
Kite, a Gilead Company
@KitePharma
Learn more about our industry-leading #celltherapy pipeline here.
-
Kite, a Gilead Company reposted
I amsterdam
@Iamsterdam
.@KitePharma has opened a new manufacturing facility in the #amsterdam Area, which will be used to create personalised treatments for cancer patients. Discover how the company’s #tech is changing the face of #healthcare: r.socialstudio.radian6.com/772c66ed-c14b-4b17-a370-b3f4f2…
-
Kite, a Gilead Company
@KitePharma
Our goal is to fundamentally change the way people think about #cancertreatment by pushing the boundaries of what is possible with genetically modified immune cells
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw discusses our focus on patients at #hbailluminate @HBAnet
-
Kite, a Gilead Company
@KitePharma
Our Global Head of Technical Operations Chuck Calderaro shares how Kite’s new European manufacturing facility will help patients in Europe and the surrounding regions access #cartcell therapy more quickly
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We are recognizing Juneteenth by encouraging our employees around the world to take today off to mark this important day. We are committed to working with our employees and partners toward a world where Black communities are free from racial injustice.
-
Kite, a Gilead Company
@KitePharma
We are pleased to attend #eha25virtual and present our latest clinical and scientific data focused on patients living with #bloodcancer
-
Kite, a Gilead Company
@KitePharma
For our colleague Niemel, “working in #celltherapy is really different than working in traditional pharma because we literally hold the patient’s blood in our hands.”
-
Kite, a Gilead Company
@KitePharma
Kite’s new European manufacturing facility will help streamline the #cartcell manufacturing process, reducing the time it takes to return cells to patients in Europe and the surrounding regions by almost a week
-
Kite, a Gilead Company
@KitePharma
#news: Today we announced the opening of our #celltherapy manufacturing facility in Europe, bringing #cart cell therapy production closer to patients in Europe and the surrounding regions
-
Kite, a Gilead Company
@KitePharma
At this year’s #eha25virtual meeting, we look forward to engaging and collaborating with our stakeholders and others in the international #hematology community
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw joined industry experts to share insights about how the #covid19 pandemic has impacted patients, the global biopharma industry and the medical community in “Biotechnology in the Time of COVID-19” by @jmaxlevin. Download the e-book for free until June 12th.
-
Kite, a Gilead Company
@KitePharma
On #nationalcancersurvivorsday, we celebrate the strength, resilience and courage of all those living with a history of #cancer. We are deeply honored to be part of the fight to turn more cancer patients into cancer survivors. #ncsd2020
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Gilead stands in solidarity and empathy with our Black employees, their families and African American communities everywhere and we condemn racism of any kind.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We will continue to listen to our Black/African American employees and community partners to better understand how we can be an ally. Read more from our Chairman and CEO Daniel O’Day: www.gilead.com/stories/articles/message-to-our-employees-….
-
Kite, a Gilead Company
@KitePharma
Our #cart cell therapy study in relapsed or refractory indolent non-Hodgkin lymphoma will be featured in the #asco20 Highlights of the Day Session today at 8:30am PT/11:30am ET
-
Kite, a Gilead Company
@KitePharma
How does #celltherapy manufacturing work? Join us on the Fantastic Voyage of #cart Cells. #asco20
-
Kite, a Gilead Company
@KitePharma
#news: We’ve announced the latest data from our #cart cell therapy study in relapsed or refractory indolent non-Hodgkin #lymphoma at #asco20
-
Kite, a Gilead Company
@KitePharma
We’re looking forward to virtually sharing the latest research from our industry-leading #celltherapy pipeline at #asco20
-
Kite, a Gilead Company
@KitePharma
At Kite, our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw will join industry leaders this Friday at 8am PT/11am ET for the "Breaking Through with Science" session at #hbailluminate @HBAnet
Gilead Sciences
@GileadSciences
This week we’re sponsoring the first virtual @HBAnet Illuminate 2020 event in support of inspiring leaders in healthcare and life sciences. Learn more about this event and how to attend: hbanet.org/Illuminate2020 #hbailluminate #hbaimpact
-
Kite, a Gilead Company
@KitePharma
Our Global Head of Clinical Development, Ken Takeshita, MD, shares his perspective on the first virtual #asco20 meeting
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw recently joined @IAMBiotech on the I AM BIO podcast to discuss #cancer in the #covid19 era and share how Kite has adapted our processes so we can continue to deliver patients’ T cells without disruption
-
Kite, a Gilead Company
@KitePharma
#news: We’re pleased to announce that nine abstracts submitted by Kite and @GileadSciences have been accepted for #asco20
-
Kite, a Gilead Company
@KitePharma
We are honored to receive a 2020 Sustainable Quality Award from the Santa Monica Chamber of Commerce (@santamonicabiz), @SustainableSM and @sustainablework recognizing Kite for excellence in stewardship of the environment
-
Kite, a Gilead Company
@KitePharma
True or False: For patients with relapsed or refractory mantle cell #lymphoma, remission gets shorter and shorter with each subsequent relapse. #lymsm
Kite, a Gilead Company
@KitePharma
POLL: The answer is True.
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Today we published our Year in Review 2019, which provides an in-depth look at our efforts to develop transformative medicines, support employees, partner with communities around the world and grow our business sustainably. Read more: www.gilead.com/news-and-press/annual-report/year-in-revie….
-
Kite, a Gilead Company
@KitePharma
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin #lymphoma that is highly aggressive following relapse #lymsm
-
Kite, a Gilead Company
@KitePharma
During #labweek, we extend our heartfelt gratitude to lab professionals around the world – including those at Kite. Thank you for your daily focus on patients.
-
Kite, a Gilead Company
@KitePharma
At Kite, we're committed to reducing our environmental impact. One of the ways we're doing this is by limiting our consumption of single-use plastics and aluminum in our offices worldwide. #earthday
-
Kite, a Gilead Company
@KitePharma
Kite, @GileadSciences and @oNKo_innate announce research collaboration to support the discovery and development of cancer immunotherapies focused on natural killer (NK) cells
-
Kite, a Gilead Company
@KitePharma
#icymi: People living with #cancer already have a lot to navigate, and now they are also facing additional stress and uncertainty that #covid19 brings. Kite CEO Christi Shaw shares how Kite team members are supporting each other in order to best meet the needs of #cancer patients
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
We are also donating $1 million each to @SMC_Strong and @MayorsFundLA to provide support for families & small businesses in California. Read more about our efforts to support organizations & individuals impacted by COVID-19: www.gilead.com/news/news-details/2020/gilead-announces-$2….
-
Kite, a Gilead Company reposted
Gilead Sciences
@GileadSciences
Today we launched the global Gilead CARES Grantee Fund, which will provide up to $20 million in financial support to current grantees facing hardships due to the COVID-19 pandemic.
-
Kite, a Gilead Company
@KitePharma
In addition to @GileadSciences’ philanthropic efforts to support nonprofit organizations impacted by #covid19, Kite is making a donation of $1 million to @MayorsFundLA, which provides support for families, small businesses & healthcare workers in LA
-
Kite, a Gilead Company
@KitePharma
Thank you to healthcare heroes everywhere who are working tirelessly to improve the lives of people impacted by #covid19 around the globe – we salute you. #worldhealthday
-
Kite, a Gilead Company
@KitePharma
We’re excited to announce a new collaboration with Teneobio to develop dual-targeting CAR T therapies in #multiplemyeloma
-
Kite, a Gilead Company
@KitePharma
Today, results from the pivotal trial of our investigational #cartcell therapy for mantle cell lymphoma (MCL) were published in @NEJM
-
Kite, a Gilead Company
@KitePharma
“During moments of global stress, it’s up to organizational leaders to take action so we come together to fulfill our purpose of helping patients who need us even more now.” – Kite CEO Christi Shaw #coronavirus #covid19
-
Kite, a Gilead Company
@KitePharma
Thank you to all healthcare workers around the world – we are indebted to you for your service. #covid19
-
Kite, a Gilead Company
@KitePharma
Our top priority is to minimize any potential impact of #covid19 on the manufacture and supply of Kite’s #cartcell therapies to the patients who need them. There is currently no risk of commercial or clinical trial supply disruption in the U.S.
Kite, a Gilead Company
@KitePharma
Following the European-US ban on passenger travel, we identified alternative shipment options to ensure that patients in Europe have access to Kite’s #cartcell therapies. #covid19
Kite, a Gilead Company
@KitePharma
In Europe, we are working to address any temporary delays related to border closures, however shipment of patient cells is expected to continue across Europe. #covid19
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw was recently named one of 11 influential women in advanced therapies by @Phacilitate. Congratulations to all those who were recognized!
-
Kite, a Gilead Company
@KitePharma
At Kite, every day brings a new opportunity to push the boundaries of what is possible with #celltherapy. Come change the future of #cancer treatment with us.
-
Kite, a Gilead Company
@KitePharma
We must all join forces to accelerate gender equality and help create an #eachforequal world. #iwd2020 #internationalwomensday
-
Kite, a Gilead Company
@KitePharma
We’re grateful for our Kite team members across the globe who dedicate their days to building the next generation of cell therapies. #employeeappreciationday
-
Kite, a Gilead Company
@KitePharma
Every second counts for someone living with #bloodcancer. Through advances in #celltherapy manufacturing, we’re committed to getting patients’ reengineered cells back to them as quickly and safely as possible.
-
Kite, a Gilead Company reposted
The Medicine Maker
@medicine_maker
Bethany Dudek, Executive Director, Quality Head Europe @KitePharma, walks us through the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.
themedicinemaker.com/manufacture/car-t-cell-therapy-redef… -
Kite, a Gilead Company
@KitePharma
Our team in the UK is honored to receive the award for Best Pharmaceutical Partnership with the National Healthcare Service for their collaboration in bringing #cart to the UK at this year’s @HSJPartnership Awards
-
Kite, a Gilead Company
@KitePharma
We are proud our ZUMA-2 study was awarded ‘Best Abstract’ at #tctm2020. Thank you to all of the authors who supported the presentation!
-
Kite, a Gilead Company
@KitePharma
At Kite, we are creating possible by remaining focused on the cure
Gilead Sciences
@GileadSciences
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet.
Come see what’s next: www.gilead.com/stories/articles/creating-possible. -
Kite, a Gilead Company
@KitePharma
#celltherapy manufacturing is a complex and carefully controlled process. Our teams work closely together to ensure that reengineered cells are delivered rapidly and reliably back to patients who need them.
-
Kite, a Gilead Company
@KitePharma
Honoring #blackhistorymonth with Gilead's Leadership Organization of Black Employees (GLOBE) by celebrating the influential minds and voices that have shaped history
-
Kite, a Gilead Company
@KitePharma
Before #cartcells can recognize and target #cancer cells, they must go through an important transformation – beginning with leukapheresis
-
Kite, a Gilead Company
@KitePharma
When you’re engineering a patient’s own white blood cells to fight cancer, those cells must first undergo a transformation that will prepare them for the journey of a lifetime. Welcome to the world of CAR T cell therapy.
-
Kite, a Gilead Company
@KitePharma
On #valentinesday we extend our heartfelt appreciation to Kite team members around the world for their dedication to our mission and the patients we serve ♥️
-
Kite, a Gilead Company
@KitePharma
True or False: Non-Hodgkin #lymphoma (NHL) is the 7th most commonly diagnosed cancer in the U.S.
Kite, a Gilead Company
@KitePharma
If you answered "true" you’re correct
-
Kite, a Gilead Company reposted
HemOnc Today
@HemOncToday
.@US_FDA grants priority review to @KitePharma @GileadSciences CAR-T for mantle cell lymphoma www.healio.com/news/hematology-oncology/20200210/fda-gran…
-
Kite, a Gilead Company
@KitePharma
Today we announced FDA acceptance of a #bla filing and priority review for our second #cartcell therapy.
-
Kite, a Gilead Company
@KitePharma
#dyk: According to @theNCI, an estimated 5,930 cases of acute lymphoblastic #leukemia (ALL) were diagnosed in 2019
-
Kite, a Gilead Company
@KitePharma
"As we look ahead to the next 30 years, there is reason to be more energized than ever about the path forward." - Kite CEO Christi Shaw on #worldcancerday. #iamandiwill
-
Kite, a Gilead Company
@KitePharma
What is the bravest thing we can do about #cancer? Come together, says Kite CEO Christi Shaw. #worldcancerday #iamandiwill
-
Kite, a Gilead Company
@KitePharma
We all know someone who has been affected by #cancer. On February 4, join us in raising awareness by sharing how you’re committed to reducing the impact of the disease. #worldcancerday #iamandiwill @uicc
-
Kite, a Gilead Company
@KitePharma
We are pleased to join @EHA_Hematology and @TheEBMT at the 2nd European CAR T Cell Meeting in Sitges, Spain this week to discuss the latest research in #celltherapy
-
Kite, a Gilead Company
@KitePharma
Today the Marketing Authorization Application for our second #cartcell therapy was validated for review by the European Medicines Agency
-
Kite, a Gilead Company
@KitePharma
We were honored to attend @PhRMA’s Researcher Day in Maryland today and discuss the future of #celltherapy
-
Kite, a Gilead Company
@KitePharma
#dyk: Engineered TCR therapies are currently being investigated for the potential treatment of various solid tumors and blood cancers?
-
Kite, a Gilead Company
@KitePharma
Our team in Amsterdam (Hoofddorp) is growing! See what a day in the life of a Cell Therapy Specialist (CTS) there looks like.
-
Kite, a Gilead Company
@KitePharma
#celltherapy manufacturing is a unique and highly scientific process that requires continual innovation and rapid turnaround
-
Kite, a Gilead Company
@KitePharma
#celltherapyacronyms: What is DOR?
-
Kite, a Gilead Company
@KitePharma
What a year! We’re ringing in the New Year with excitement as we continue to drive #celltherapy forward. See you in 2020! #happynewyear
-
Kite, a Gilead Company
@KitePharma
At Kite, we’re advancing #cartcell technology. Take a closer look at how #celltherapy works.
-
Kite, a Gilead Company
@KitePharma
Kite employees helped spread holiday cheer by donating toys for underserved children and teens in the Southern California area today. #stuffthebus #sparkoflove @abc7 @LACOFD @WeDriveU
-
Kite, a Gilead Company
@KitePharma
We were honored to host the Women at Gilead SoCal Chapter’s Career Development and Networking Event with Kimberly Lathroum (@kitepharma), @BDahiyat and @DinaAtUCLATDG at our Kite headquarters in Santa Monica last night. #stem #healthcare
-
Kite, a Gilead Company
@KitePharma
Today we announced submission of a #bla filing for our second #cartcell therapy
-
Kite, a Gilead Company
@KitePharma
Kite and @Kiniksa announce clinical collaboration in relapsed or refractory large B-cell #lymphoma: www.gilead.com/news-and-press/press-room/press-releases/2…
-
Kite, a Gilead Company
@KitePharma
#ash19 has come to an end, but there’s still more to come from us. Keep following along on Twitter for more on our advancing #celltherapy portfolio!
-
Kite, a Gilead Company
@KitePharma
Thank you to everyone who stopped by our booth to learn about Kite’s pipeline in #celltherapy at #ash19
-
Kite, a Gilead Company
@KitePharma
#dyk that mantle cell lymphoma (MCL) begins in the cells in the outer edge of the lymph node? #ash19
-
Kite, a Gilead Company
@KitePharma
We’re sharing results from the first evaluation of #cartcell therapy in mantle cell #lymphoma (MCL). Head to Hall D at 3:30pm to join the conversation. #ash19
-
Kite, a Gilead Company
@KitePharma
Join us now in room W230 as we present a real-world analysis of #cartcell therapy. #ash19
-
Kite, a Gilead Company
@KitePharma
We’re here at #ash19 sharing our #celltherapy research in hematologic malignancies. #bloodcancer
-
Kite, a Gilead Company
@KitePharma
We’re committed to advancing #celltherapy for those who depend on these transformative treatments for #bloodcancer. #ash19
-
Kite, a Gilead Company
@KitePharma
#cartcell therapy is a personalized immunotherapy where a person’s own T cells are engineered to target #cancer cells. It involves a multistep process from collecting the cells to infusing them back into the patient. #ash19
-
Kite, a Gilead Company
@KitePharma
We’re sharing results from our safety management study for #cartcell therapy in Hall E2 at 2:30pm! #ash19
-
Kite, a Gilead Company
@KitePharma
We’re excited to share our survival data at three years for #cartcell therapy today at #ash19. www.gilead.com/news/news-details/2019/kite-announces-long…
-
Kite, a Gilead Company
@KitePharma
At #ash19? Join us for our presentation discussing survival data at three years for #cartcell therapy (Abstract #203) in W415A at 1pm.
-
Kite, a Gilead Company
@KitePharma
We’ll be sharing survival data at three years for #cartcell therapy today at #ash19. Stop by the presentation today at 1pm in W415A.
-
Kite, a Gilead Company
@KitePharma
Hello from #ash19! Stop by booth 1007 to learn more about our industry-leading #celltherapy portfolio
-
Kite, a Gilead Company
@KitePharma
At #ash19? We’re excited to be here in Orlando to present findings from our latest #celltherapy research.
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw discusses how biopharma breakthroughs are revolutionizing #healthcare at #forbeshealth
-
Kite, a Gilead Company
@KitePharma
Kite CEO Christi Shaw is about to take the stage at #forbeshealth for the “Breaking into the Golden Age of Biopharma” panel with fellow industry leaders @ForbesHealth
-
Kite, a Gilead Company
@KitePharma
True or False: Diffuse large B-cell #lymphoma (DLBCL) is the most frequently diagnosed type of lymphoma globally. #ash19
Kite, a Gilead Company
@KitePharma
If you answered “true,” you’re correct. #ash19
-
Kite, a Gilead Company
@KitePharma
Our CEO Christi Shaw will discuss how innovative therapies are revolutionizing healthcare tomorrow @ForbesHealth Summit. Stay tuned for her outlook on biopharma breakthroughs at #forbeshealth
-
Kite, a Gilead Company
@KitePharma
This weekend we’re heading to Orlando for #ash19 with @ASH_hematology! Follow along for the latest research in #celltherapy www.gilead.com/news/news-details/2019/kite-to-present-new…
-
Kite, a Gilead Company
@KitePharma
We’re thrilled to be back! Follow us to stay up to date on our industry-leading #celltherapy portfolio
-
Kite, a Gilead Company
@KitePharma
Tonight we #lightitred for Lymphoma Awareness. Learn more www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8342981 #wlad #lymphoma #bloodcancerawarenessmonth $Kite
-
Kite, a Gilead Company
@KitePharma
$KITE acquired by $GILD for $11.9 Billion, $180 per share www.businesswire.com/news/home/20170828005415/en/Gilead-S…
-
Kite, a Gilead Company
@KitePharma
We highlighted the @JCO_ASCO publication of @NCI MAGE A3 TCR data in patients with solid tumors. Read more: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1037572 $Kite
-
Kite, a Gilead Company
@KitePharma
Today at 2:00pm ET we will present at the Canaccord conference. Tune in to our webcast ir.kitepharma.com/releasedetail.cfm?ReleaseID=1035318 $Kite
-
Kite, a Gilead Company
@KitePharma
Today at 8:30am ET / 5:30am PT we will hold our Q217 earnings conference call ir.kitepharma.com/releasedetail.cfm?ReleaseID=1036453 $Kite
-
Kite, a Gilead Company
@KitePharma
Tune in to our Q217 earnings conference call tomorrow at 8:30am ET / 5:30am PT. For full details see here ir.kitepharma.com/releasedetail.cfm?ReleaseID=1035313 $Kite
-
Kite, a Gilead Company
@KitePharma
Landmark Study of Refractory Aggressive NHL (SCHOLAR-1) Outcomes Published in @bloodjournal ir.kitepharma.com/releasedetail.cfm?ReleaseID=1035919 $Kite
-
Kite, a Gilead Company
@KitePharma
We’re proud to submit the first CAR-T cell therapy MAA application to the EMA ir.kitepharma.com/releasedetail.cfm?ReleaseID=1035076 $Kite
-
Kite, a Gilead Company
@KitePharma
See @MolTherapy pub of @theNCI data - CRs up to 56+ mos. in pts w/ refractory agg NHL after anti-CD19 CAR-T ir.kitepharma.com/releasedetail.cfm?ReleaseID=1033805 $KITE
-
Kite, a Gilead Company
@KitePharma
Our leadership in CAR-T earned us the #7 spot on @MIT's Smartest Companies list of 2017. Get the details: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1031468 $Kite
-
Kite, a Gilead Company
@KitePharma
This past Sunday, we walked in honor & memory of those whose lives have been touched by @Lymphoma. #walkwithlrf
-
Kite, a Gilead Company
@KitePharma
We presented an updated analysis from Phase 1 ZUMA-3 CAR T Trial in adults w/ high burden r/r ALL. #asco17 $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1029019
-
Kite, a Gilead Company
@KitePharma
#icymi We received @US_FDA priority review for Axicabtagene Ciloleucel. Get the details: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1028075 $kite
-
Kite, a Gilead Company
@KitePharma
$Kite to present on its lead CAR-T therapy development program at #asco17 ir.kitepharma.com/releasedetail.cfm?ReleaseID=1026892
-
Kite, a Gilead Company
@KitePharma
Kite Reports First Quarter Financial Results: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1025235
-
Kite, a Gilead Company
@KitePharma
We are developing the future of TCR technology www.kitepharma.com/tcr-video Learn how it will change cancer treatment & share with a friend $Kite
-
Kite, a Gilead Company
@KitePharma
Our collaborator @theNCI Dr. Rosenberg's pioneering work has shown incredible potential for the treatment of cancer kitepharma.com/collaborations/dr-steve-rosenberg-chief-of…
-
Kite, a Gilead Company
@KitePharma
April is National #cancercontrol month. We're committed to developing next-generation technologies to fight cancer cells in the body. $Kite
-
Kite, a Gilead Company
@KitePharma
Please visit: discovercart.com to learn more about CAR T Immunotherapy
-
Kite, a Gilead Company
@KitePharma
Thanks @ #aacr17! If you missed us this year, you can find more information about ZUMA-1 data here: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1019687 $Kite
-
Kite, a Gilead Company
@KitePharma
Its #aacr17 - we're revealing preclinical details on our development of KITE-585 targeting BCMA! 3:30 EDT Ballroom A-B, Level 3 $Kite
-
Kite, a Gilead Company
@KitePharma
Today is the day for our poster KITE-585 targeting BCMA! Come meet us @ Halls A-C, Poster Section 6 from 1-5pm EDT #aacr17 $Kite
-
Kite, a Gilead Company
@KitePharma
Going to #aacr17? View our presentations 4:05-4:25 EDT to learn more about ZUMA-1 & CAR-T cell therapy $Kite
-
Kite, a Gilead Company
@KitePharma
Kick off your Saturday @ #aacr17 by getting to know the incredible minds at $Kite. We're at booth 251
-
Kite, a Gilead Company
@KitePharma
Today our scientists head to Washington DC to discuss our ZUMA-1 CAR-T trial data @ #aacr17 $Kite
-
Kite, a Gilead Company
@KitePharma
We are proud to announce that we have completed our BLA submission for axicabtagene ciloleucel! Learn more: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1019623 $Kite
-
Kite, a Gilead Company
@KitePharma
#aacr17 day 1 starts tomorrow! We look forward to sharing our CAR-T therapy ZUMA-1 trial data on 4/2 at 4:04pm EDT $Kite
-
Kite, a Gilead Company
@KitePharma
#aacr17 highlights innovative cancer science from all over the world. Don't miss our ZUMA-1 primary analysis on 4/2 $Kite
-
Kite, a Gilead Company
@KitePharma
Join us at #aacr17 as we present data on our CAR-T therapy ZUMA-1 trial. $Kite More details: ir.kitepharma.com/releasedetail.cfm?ReleaseID=1019378
-
Kite, a Gilead Company
@KitePharma
Interested in joining #kitepharma? We’re looking for Case Managers! Click here to learn more: careers.jobscore.com/careers/kitepharma/jobs/case-manager…
-
Kite, a Gilead Company
@KitePharma
#kitepharma is hiring a Reimbursement & Appeals Specialists team. Apply here: careers.jobscore.com/careers/kitepharma/jobs/specialist-r…
-
Kite, a Gilead Company
@KitePharma
#kitepharma is looking for a Director of Program Operations. Click here to soar with us: careers.jobscore.com/careers/kitepharma/jobs/director-pro…
-
Kite, a Gilead Company
@KitePharma
#kitepharma highlighted the @JCO_ASCO publication from @NCI Anti-CD19 CAR T-Cell data in patients with #nhl $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1017388
-
Kite, a Gilead Company
@KitePharma
Kite to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017 ir.kitepharma.com/releasedetail.cfm?ReleaseID=1014748
-
Kite, a Gilead Company
@KitePharma
Please visit: www.discovercart.com to learn more about CAR T Immunotherapy
-
Kite, a Gilead Company
@KitePharma
Well-deserved praise for groundbreaking work in immunotherapy from our partner, Dr. Stephen Rosenberg & team @theNCI on.today.com/2jUtQIX
-
Kite, a Gilead Company
@KitePharma
#kitepharma & Fosun Pharma Establish JV in China to Develop & Commercialize T-Cell Therapies for Cancer $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1007279
-
Kite, a Gilead Company
@KitePharma
#kitepharma Establishes a Strategic Partnership with @DaiichiSankyo for axi-cel in Japan $KITE #jpm17 ir.kitepharma.com/releasedetail.cfm?ReleaseID=1007223
-
Kite, a Gilead Company
@KitePharma
#kitepharma Enhances Commercial Expertise with Appointment of Ian T. Clark from @Genentech to its BOD $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1006639
-
Kite, a Gilead Company
@KitePharma
#kitepharma CEO Dr. Arie Belldegrun to present at #jpm17 on Jan 11th @ 4:30 PM $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1006295
-
Kite, a Gilead Company
@KitePharma
#kitepharma Submits KITE-718 IND, Investigational Next Gen TCR Therapy Targeting MAGE A3/A6 for solid tumors $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1005990
-
Kite, a Gilead Company
@KitePharma
#kitepharma: Successful Defense on Roberts Patent; To Appeal USPTO on Narrow Patent for CD28 CAR-T Product $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1004781
-
Kite, a Gilead Company
@KitePharma
#kitepharma & @vinetiworks Partner to Develop Best-In Class Logistics & Analytics for Engineered T-cell Therapies ir.kitepharma.com/releasedetail.cfm?ReleaseID=1003941
-
Kite, a Gilead Company reposted
NEJM
@NEJM
Original Article: T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer www.nejm.org/doi/full/10.1056/NEJMoa1609279
-
Kite, a Gilead Company reposted
The New York Times
@nytimes
She wouldn't take no for an answer, and she got into a study that has left her cancer free www.nytimes.com/2016/12/07/health/cancer-immunotherapy.ht…
-
Kite, a Gilead Company
@KitePharma
#kitepharma ZUMA-1 presentation selected for “Best of ASH” 2016 #ash2016 $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1002918 - Thank you @ASH_hematology
-
Kite, a Gilead Company
@KitePharma
#kitepharma Initiates Rolling Submission of BLA with US FDA for KTE-C19 in r/r Aggressive NHL $KITE #ash16 ir.kitepharma.com/releasedetail.cfm?ReleaseID=1002522
-
Kite, a Gilead Company
@KitePharma
#kitepharma Presents Prelim Analysis of Ph 1 ZUMA-3/4 of KTE-C19 in Adult & Ped r/r ALL #ash16 $KITE ir.kitepharma.com/releasedetail.cfm?ReleaseID=1002521
-
Kite, a Gilead Company
@KitePharma
Please visit us at Booth 2455 at #ash16 to learn more about #car-T and #immunotherapy #kite
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Appoints Jian Irish, PhD as Senior Vice President of Supply Chain ir.kitepharma.com/releasedetail.cfm?ReleaseID=1001722 #kitepharma $KITE
-
Kite, a Gilead Company
@KitePharma
#kitepharma to Present Interim Results from ZUMA-1 Pivotal Trial of KTE-C19 in Late-Breaking Session at #ash16 ir.kitepharma.com/releasedetail.cfm?ReleaseID=1000556 $KITE
-
Kite, a Gilead Company
@KitePharma
November is #nationalcaregiversmonth! Please check out resources from our partner @theNCI www.cancer.gov/about-cancer/coping/caregiver-support
-
Kite, a Gilead Company
@KitePharma
Join our partner @LLSusa for their Light the Night Walk this evening in San Francisco pages.lightthenight.org/gba/SanFran16 #bloodcancer
-
Kite, a Gilead Company
@KitePharma
Join #kitepharma for our 3rd quarter results call today at 8:30amPT/11:30am ET. Webcast link here: edge.media-server.com/m/p/6ed4q3zw $KITE
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Reports Third Quarter 2016 Financial Results ir.kitepharma.com/releasedetail.cfm?ReleaseID=998514 #kitepharma $KITE
-
Kite, a Gilead Company
@KitePharma
T cells are key to immune system's ability to detect & kill cancer. Learn about #immunotherapy: www.kitepharma.com/technology #kitepharma $KITE
-
Kite, a Gilead Company
@KitePharma
#kitepharma is presenting @CreditSuisse 25th Annual Healthcare Conference today at 1:30pm PST. Webcast here: cc.talkpoint.com/cred001/110716a_as/?entity=89_KOKVUGS $KITE
-
Kite, a Gilead Company
@KitePharma
Kite to Present KTE-C19 Clin & Mfg Data From ZUMA-1 (agg NHL), ZUMA-3 and ZUMA-4 (ALL) at #ash16 ir.kitepharma.com/releasedetail.cfm?ReleaseID=997438 #kitepharma #kite
-
Kite, a Gilead Company reposted
Rep. Ted Lieu
@RepTedLieu
Had a great time touring the @KitePharma manufacturing facility in El Segundo today! Amazing company leading the way to cure cancer.
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Report Third Quarter 2016 Financial Results on November 9, 2016 ir.kitepharma.com/releasedetail.cfm?ReleaseID=996978 #kitepharma $kite
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Present at November 2016 Investor Conferences ir.kitepharma.com/releasedetail.cfm?ReleaseID=996131 #kitepharma $KITE
-
Kite, a Gilead Company
@KitePharma
Missed #kiteinvestorday? Read how Kite is paving the way for a new cancer treatment paradigm #kitepharma $Kite ir.kitepharma.com/releasedetail.cfm?ReleaseID=994338
-
Kite, a Gilead Company
@KitePharma
Shawn Tomasello: Kite has right team, experience & approach to successfully launch KTE-C19 if approved #kiteinvestorday #kitepharma $Kite
-
Kite, a Gilead Company
@KitePharma
Dr. Jeff Wiezorek shows expansion of Kite’s clinical development of KTE-C19 in additional indications #kiteinvestorday #kitepharma $Kite
-
Kite, a Gilead Company
@KitePharma
Dr. Margo Roberts - T cells 2.0: Kite is advancing new technologies for next gen CAR/TCR therapies #kiteinvestorday #kitepharma $Kite
-
Kite, a Gilead Company
@KitePharma
Dr. Ton Schumacher: Kite is exploiting natural affinity TCRs to target solid tumors #kiteinvestorday #kitepharma $Kite
-
Kite, a Gilead Company
@KitePharma
Kite unveils 4 new near-term clinical programs for CARs in AML, MM & TCRs in NSCL/Bladder & Cervical/HNC #kiteinvestorday #kitepharma $Kite
-
Kite, a Gilead Company
@KitePharma
Tune in to #kiteinvestorday at 12:00pm ET here: edge.media-server.com/m/p/4c5ei5je
-
Kite, a Gilead Company
@KitePharma
Kite Appoints Chris Nowers as Head of Europe to Lead Commercial Operations & Advance the CAR/TCR Therapy Portfolio ir.kitepharma.com/releasedetail.cfm?ReleaseID=993410
-
Kite, a Gilead Company
@KitePharma
Kite Hosting Investor Day on Oct. 18 – Focus on CAR/TCR Pipeline, Next Gen R&D, and KTE-C19 Launch Readiness ir.kitepharma.com/releasedetail.cfm?ReleaseID=992995
-
Kite, a Gilead Company
@KitePharma
Kite Initiates Phase 1b/2 Combination Study for KTE-C19 & Atezolizumab in Patients w/ Refractory DLBCL w/ @genentech ir.kitepharma.com/releasedetail.cfm?ReleaseID=992426
-
Kite, a Gilead Company
@KitePharma
Listen to our webcast of the ZUMA-1 topline data today at 4:30pm, ET, here: edge.media-server.com/m/p/yqxauft6
-
Kite, a Gilead Company
@KitePharma
Kite Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive NHL ir.kitepharma.com/releasedetail.cfm?ReleaseID=990947
-
Kite, a Gilead Company
@KitePharma
Announcing Excl. License w/ @NIH for Neoantigen Directed TCR Prod. Candidates to Treat Solid Tumors Expressing KRAS ir.kitepharma.com/releasedetail.cfm?ReleaseID=990203
-
Kite, a Gilead Company
@KitePharma
We're proud to support #bloodcancerawarenessmonth! Join us in raising awareness for @LLSusa
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Participate in September 2016 Investor Conferences ir.kitepharma.com/releasedetail.cfm?ReleaseID=987350
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Advisors & Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award ir.kitepharma.com/releasedetail.cfm?ReleaseID=984954
-
Kite, a Gilead Company
@KitePharma
Many thanks to the @Dodgers for having us on a beautiful Sunday afternoon #dodgerswin #baseball #kiteculture
-
Kite, a Gilead Company
@KitePharma
Check Out Our Presentation @CanaccorGenuity 36th Annual Growth Conference Today at 2:00pm EDT Here: wsw.com/webcast/canaccord23/register.aspx?conf=canaccord2…
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Reports Second Quarter 2016 Financial Results ir.kitepharma.com/releasedetail.cfm?ReleaseID=983481
-
Kite, a Gilead Company
@KitePharma
Listen To Our Q2 2016 Financial Results Webcast Today At 4:30pm EDT Here: edge.media-server.com/m/p/x7t42f6k
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference ir.kitepharma.com/releasedetail.cfm?ReleaseID=982748
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016 ir.kitepharma.com/releasedetail.cfm?ReleaseID=982182
-
Kite, a Gilead Company
@KitePharma
Kite Announces Excl. License w/ @NIH for Fully Human Anti-CD19 CAR Product Candidate to Treat B-Cell Malignancies ir.kitepharma.com/releasedetail.cfm?ReleaseID=981503
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies ir.kitepharma.com/releasedetail.cfm?ReleaseID=981016
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Completes Enrollment of All Patients w/ DLBCL in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1) ir.kitepharma.com/releasedetail.cfm?ReleaseID=978668
-
Kite, a Gilead Company
@KitePharma
Entrance to Kite's Commercial Manufacturing Facility #kitepharma #kitegrandopening #immunotherapy
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Opens State-Of-The-Art T-Cell Therapy Manufacturing Facility ir.kitepharma.com/releasedetail.cfm?ReleaseID=976420
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Expands Development of TCR Therapies Targeting HPV-Associated Cancers in Partnership with @theNCI ir.kitepharma.com/releasedetail.cfm?ReleaseID=976295
-
Kite, a Gilead Company
@KitePharma
Kite to Highlight Key Data From CAR T-Cell Pipeline in Oral Presentations at 2016 @EHA_Hematology Annual Congress ir.kitepharma.com/releasedetail.cfm?ReleaseID=974822
-
Kite, a Gilead Company
@KitePharma
Kite Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cel (SCHOLAR-1)l ir.kitepharma.com/releasedetail.cfm?ReleaseID=974372 #asco16
-
Kite, a Gilead Company
@KitePharma
Kite Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients W/ Chemorefractory NHL ir.kitepharma.com/releasedetail.cfm?ReleaseID=974371 #asco16
-
Kite, a Gilead Company
@KitePharma
Kite & Cell Design Labs Announce Exclusive Research Collab. Using Molecular ‘On/Off Switches’ for CAR T-Cell Therapy ir.kitepharma.com/releasedetail.cfm?ReleaseID=973947
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Granted Access to Priority Medicines (PRIME) EU Regulatory Initiative for KTE-C19 ir.kitepharma.com/releasedetail.cfm?ReleaseID=973840
-
Kite, a Gilead Company
@KitePharma
Kite to Highlight Key Data From Engineered CAR T Cell Therapy Pipeline at The 2016 @ASCO Annual Meeting #asco16 ir.kitepharma.com/releasedetail.cfm?ReleaseID=973576
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Present at June 2016 Investor Conferences ir.kitepharma.com/releasedetail.cfm?ReleaseID=973168
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson as Chief Financial Officer ir.kitepharma.com/releasedetail.cfm?ReleaseID=971165
-
Kite, a Gilead Company
@KitePharma
Kite Reports First Quarter 2016 Financial Results ir.kitepharma.com/releasedetail.cfm?ReleaseID=969997. Listen to Our Live Webcast at 4:30pm, ET: ir.kitepharma.com/eventdetail.cfm?EventID=171561
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Report First Quarter 2016 Financial Results on May 9, 2016 ir.kitepharma.com/releasedetail.cfm?ReleaseID=968863
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Blood Cancer Indications ir.kitepharma.com/releasedetail.cfm?ReleaseID=968528
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) ir.kitepharma.com/releasedetail.cfm?ReleaseID=967817
-
Kite, a Gilead Company
@KitePharma
Proud of Kite SAB Member, Ron Levy, for earning the Lloyd J. Old Award in Cancer Immunology at #aacr16
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 @AACR: ir.kitepharma.com/releasedetail.cfm?ReleaseID=965836 #aacr16
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Commends Scientific Advisory Board Members on Awards Received from @AACR ir.kitepharma.com/releasedetail.cfm?ReleaseID=965628 #aacr16
-
Kite, a Gilead Company
@KitePharma
Best Wishes to Kite SAB Member Toni Ribas for winning the Richard and Hinda Rosenthal Award at #aacr16
-
Kite, a Gilead Company
@KitePharma
Kite’s John Rossi & Timothy Langer Present on Manufacturing of KTE-C19 in ZUMA-1 & Review of @theNCI anti-CD19 CAR-T Cells #aacr16
-
Kite, a Gilead Company
@KitePharma
On behalf of @theNCI, Yong-Chen W. Lu Ph.D., Presenting Phase 1 Study of an HLA-DPB1*0401-restricted TCR Targeting MAGE-A3 #aacr16
-
Kite, a Gilead Company
@KitePharma
Kite EU’s Ton Schumacher is presenting in Opening Plenary Session of #aacr16 on T-Cell Recognition of Human Cancer
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs @AACR ir.kitepharma.com/releasedetail.cfm?ReleaseID=965419 #aacr16
-
Kite, a Gilead Company
@KitePharma
Congratulations to our Scientific Advisory Board Members, Dr. James Allison and Dr. Antoni Ribas, for their involvement with @ParkerICI
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients w/ NHL ir.kitepharma.com/releasedetail.cfm?ReleaseID=961129 @Genentech
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces Clinical & Manufacturing Updates on KTE-C19 & MAGE-A3 Product Candidates at @AACR ir.kitepharma.com/releasedetail.cfm?ReleaseID=961028 #aacr16
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Present at March 2016 Investor Conferences ir.kitepharma.com/releasedetail.cfm?ReleaseID=958837
-
Kite, a Gilead Company
@KitePharma
Please Join Us On Feb 29 at 1:30pm PT For Our 2015 Financial Results Webcast. Link Can Be Found Here: ir.kitepharma.com/events.cfm
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Augments Commercial Leadership Team: KTE-C19 Commercial Readiness Planning Underway ir.kitepharma.com/releasedetail.cfm?ReleaseID=956991
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 ir.kitepharma.com/releasedetail.cfm?ReleaseID=956746
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Participate in the 2016 RBC Capital Markets Global Healthcare Conference ir.kitepharma.com/releasedetail.cfm?ReleaseID=955174
-
Kite, a Gilead Company
@KitePharma
Make Sure to Check Out Kite's Presentation at #jpm16 on Jan, 14th at 8:30am PT. Link to webcast here: ir.kitepharma.com/eventdetail.cfm?EventID=168620
-
Kite, a Gilead Company
@KitePharma
Kite and @LUMC_Leiden Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers ir.kitepharma.com/releasedetail.cfm?ReleaseID=950100
-
Kite, a Gilead Company reposted
Nasdaq Exchange
@NasdaqExchange
Want to learn about the latest in CAR-T treatments? Follow @KitePharma $KITE
-
Kite, a Gilead Company
@KitePharma
Kite Expands its Clinical & Research Partnership w/ @theNCI for Next-Gen CAR Programs to Treat B-Cell Malignancies ir.kitepharma.com/releasedetail.cfm?ReleaseID=949308
-
Kite, a Gilead Company
@KitePharma
Kite Pharma To Present At The 34th Annual J.P. Morgan Healthcare Conference on Thursday, Jan 14 at 8:30am PT #jpm16 ir.kitepharma.com/releasedetail.cfm?ReleaseID=949022
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Final Poster Presentation at #ash15 Day 3
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the #ash15 Annual Meeting ir.kitepharma.com/releasedetail.cfm?ReleaseID=945909
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Presents Phase 1 Results from ZUMA-1 at the #ash15 Annual Meeting ir.kitepharma.com/releasedetail.cfm?ReleaseID=945874
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for r/r ALL in Children and Young Adults ir.kitepharma.com/releasedetail.cfm?ReleaseID=945791
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for Treatment of Refractory DLBCL, PMBCL & TFL ir.kitepharma.com/releasedetail.cfm?ReleaseID=945790
-
Kite, a Gilead Company
@KitePharma
Check out the picture below to see the details of Kite Pharma's #ash15 Day 1 Presentation.
-
Kite, a Gilead Company
@KitePharma
Kite Pharma & @GEResearch Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies ir.kitepharma.com/releasedetail.cfm?ReleaseID=945374
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Initiates ZUMA-3 Study to Support Registration of KTE-C19 for r/r ALL in Adult Subjects ir.kitepharma.com/releasedetail.cfm?ReleaseID=945128
-
Kite, a Gilead Company reposted
Amgen 🧪🔬🧬
@Amgen
Welcome to Twitter @KitePharma. We're excited to continue our collaboration investigating novel CAR T cell immunotherapies
-
Kite, a Gilead Company reposted
CAR-TCR
@CAR_TCell
The father of CAR-T, Zelig Eshhar introducing the mother of CAR-T: Margo Roberts from @KitePharma #cart15
-
Kite, a Gilead Company reposted
BCLA
@Team_BCLA
Future of Immunotherapy @CNSI_UCLA: Zach Zimmerman @Amgen and Margo Roberts @KitePharma in our panel! Sign up now! immunotherapy.eventbrite.com
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update ir.kitepharma.com/releasedetail.cfm?ReleaseID=942506
-
Kite, a Gilead Company
@KitePharma
Kite Initiates Ph. 2 Study of KTE-C19 (ZUMA-2) in Pts. with r/r MCL to Support Registration for a Second Indication ir.kitepharma.com/releasedetail.cfm?ReleaseID=941501
-
Kite, a Gilead Company
@KitePharma
Presenting Four Abstracts, w/ Data from KTE-C19 Ph. 1 Study in Pts. w/ Refractory, Aggressive NHL (ZUMA-1) at #ash15 ir.kitepharma.com/releasedetail.cfm?ReleaseID=940923
-
Kite, a Gilead Company
@KitePharma
Kite Pharma to Present at Upcoming Investor Conferences in November 2015 ir.kitepharma.com/releasedetail.cfm?ReleaseID=940441
-
Kite, a Gilead Company
@KitePharma
Kite Pharma Initiates ZUMA-1 Phase 2 in Patients with Aggressive, Refractory NHL to Support Registration of KTE-C19 ir.kitepharma.com/releasedetail.cfm?ReleaseID=939709
-
Kite, a Gilead Company
@KitePharma
Announcing Research & License Agreement w/ @AlpineImmuneSci to Enhance Immune Response in Tumor Microenvironment ir.kitepharma.com/releasedetail.cfm?ReleaseID=938579
-
Kite, a Gilead Company
@KitePharma
Kite Announces Exclusive License with @NIH for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE ir.kitepharma.com/releasedetail.cfm?ReleaseID=937381
-
Kite, a Gilead Company
@KitePharma
We Commend Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From @AmericanCancer ir.kitepharma.com/releasedetail.cfm?ReleaseID=935510










































































































































































































